Document:

Amended and Restated Investor Rights Agreement

 Exhibit 4.3 

 
 GENOMATICA, INC. 

 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 TABLE OF CONTENTS 

 

							
	 	  	 	  	PAGE	 
			
	SECTION 1.	  	GENERAL	  	 	1	  
			
	 1.1
	  	Termination of Prior Agreement	  	 	1	  
			
	 1.2
	  	Definitions	  	 	2	  
			
	SECTION 2.	  	REGISTRATION; RESTRICTIONS ON TRANSFER	  	 	3	  
			
	 2.1
	  	Restrictions on Transfer	  	 	3	  
			
	 2.2
	  	Demand Registration	  	 	4	  
			
	 2.3
	  	Piggyback Registrations	  	 	6	  
			
	 2.4
	  	Form S-3 Registration	  	 	7	  
			
	 2.5
	  	Expenses of Registration	  	 	9	  
			
	 2.6
	  	Obligations of the Company	  	 	10	  
			
	 2.7
	  	Delay of Registration; Furnishing Information	  	 	11	  
			
	 2.8
	  	Indemnification	  	 	12	  
			
	 2.9
	  	Assignment of Registration Rights	  	 	14	  
			
	 2.10
	  	Limitation on Subsequent Registration Rights	  	 	14	  
			
	 2.11
	  	“Market Stand-Off” Agreement	  	 	14	  
			
	 2.12
	  	Agreement to Furnish Information	  	 	15	  
			
	 2.13
	  	Rule 144 Reporting	  	 	15	  
			
	 2.14
	  	Termination of Registration Rights	  	 	15	  
			
	SECTION 3.	  	COVENANTS OF THE COMPANY	  	 	16	  
			
	 3.1
	  	Basic Financial Information and Reporting	  	 	16	  
			
	 3.2
	  	Inspection Rights	  	 	17	  
			
	 3.3
	  	Reservation of Common Stock	  	 	17	  
			
	 3.4
	  	Board Committee Membership	  	 	17	  
			
	 3.5
	  	Option Pool	  	 	19	  
			
	 3.6
	  	Termination of Covenants	  	 	19	  
			
	SECTION 4.	  	RIGHTS OF FIRST REFUSAL	  	 	19	  
			
	 4.1
	  	Subsequent Offerings	  	 	19	  
			
	 4.2
	  	Exercise of Rights	  	 	20	  
			
	 4.3
	  	Issuance of Equity Securities to Other Persons	  	 	20	  
			
	 4.4
	  	Termination and Waiver of Rights of First Refusal	  	 	21	  
			
	 4.5
	  	Assignment of Rights of First Refusal	  	 	21	  
			
	 4.6
	  	Excluded Securities	  	 	21	  
			
	SECTION 5.	  	MISCELLANEOUS	  	 	22	  

  
 i 

 TABLE OF CONTENTS 

(CONTINUED) 
  

							
	 	  	 	  	PAGE	 
			
	 5.1
	  	Governing Law	  	 	22	  
			
	 5.2
	  	Successors and Assigns	  	 	22	  
			
	 5.3
	  	Entire Agreement	  	 	22	  
			
	 5.4
	  	Severability	  	 	23	  
			
	 5.5
	  	Amendment and Waiver	  	 	23	  
			
	 5.6
	  	Delays or Omissions	  	 	23	  
			
	 5.7
	  	Notices	  	 	23	  
			
	 5.8
	  	Attorneys’ Fees	  	 	24	  
			
	 5.9
	  	Titles and Subtitles	  	 	24	  
			
	 5.10
	  	Additional Investors	  	 	24	  
			
	 5.11
	  	Counterparts	  	 	24	  
			
	 5.12
	  	Aggregation of Stock	  	 	24	  
			
	 5.13
	  	Pronouns	  	 	24	  
			
	 5.14
	  	Termination	  	 	24	  

  
 ii 

 GENOMATICA, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 10th day of December 2010, by and among Genomatica, Inc., a Delaware corporation (the “Company”)
and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.” 

RECITALS 
 WHEREAS, certain of the Investors (the “Prior Investors”) are holders of the Company’s Series A Preferred Stock (the “Series A
Stock”), the Company’s Series B Preferred Stock (the “Series B Stock”) and the Company’s Series C Preferred Stock (the “Series C Stock”); 

WHEREAS, certain of the Investors are purchasing shares of the Company’s Series C-l Preferred
Stock (the “Series C-1 Stock”) pursuant to that certain Series C-l Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”);

 WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution
and delivery of this Agreement; 
 WHEREAS, the Prior Investors and the Company are
parties to an Amended and Restated Investor Rights Agreement dated January 20, 2010 (the “Prior Agreement”); 
 WHEREAS, certain of the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof in lieu of their rights and
covenants under the Prior Agreement and the undersigned parties include (i) the Company, (ii) the holders of at least a majority of the outstanding Registrable Securities, (iii) the holders of at least a majority of the outstanding
Series B Stock included in the Registrable Securities (as that term is defined in the Prior Agreement) and (iv) the holders of at least a majority of the outstanding Series C Stock included in the Registrable Securities; and 

WHEREAS, in connection with the consummation of the Financing, the parties desire to enter into
this Agreement in order to grant registration, information rights and other rights to the Investors as set forth below. 
 Now, THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 
 SECTION 1. GENERAL. 
 1.1 Termination of Prior Agreement. The Prior Agreement is hereby amended and restated to read as set forth in this Agreement and the Prior Agreement is hereby terminated, waived, released,
replaced and superseded in its entirety by this Agreement and shall have no further force or effect. 

  
 1 

 1.2 Definitions. As used in this Agreement the following terms shall
have the following respective meanings: 
 (a) “Exchange Act” means the
Securities Exchange Act of 1934, as amended. 
 (b) “Form S-3” means such form
under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other
documents filed by the Company with the SEC. 
 (c) “Holder” means any person
owning of record Registrable Securities that have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof; provided that a holder of record of outstanding Shares
shall . be deemed to be a Holder of the Registrable Securities issuable upon the conversion of such outstanding Shares owned of record by such Holder. 
 (d) “Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock (as defined in the Purchase Agreement) registered
under the Securities Act. 
 (e) “Preferred Directors” means those members of the
Company’s Board of Directors who, pursuant to the terms of the Company’s Amended and Restated Certificate of Incorporation, as it may be amended, are elected solely by the vote of holders of the Company’s Preferred Stock. 

(f) “Register,” “registered,” and “registration” refer
to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(g) “Registrable Securities” means (a) Common Stock of the Company
(“Common Stock”) issuable or issued upon conversion of the Shares and (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as)
a dividend or other distribution with respect to, or in exchange for or in replacement of Shares or any Common Stock described in clause (a) or in this clause (b). Notwithstanding the foregoing, Registrable Securities shall not include any
securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144 or (ii) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned.

 (h) “Registrable Securities then outstanding” shall be the number of shares of
the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or convertible securities (including without limitation convertible Preferred
Stock of the Company). 
 (i) “Registration Expenses” shall mean all expenses
incurred by the Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements not
to exceed $75,000 of a single special counsel 

  
 2 

 
for the Holders for each such registration, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of
regular employees of the Company which shall be paid in any event by the Company). 
 (j)
“SEC” or “Commission” means the Securities and Exchange Commission. 
 (k) “Securities Act” shall mean the Securities Act of 1933, as amended. 
 (l) “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale. 

(m) “Shares” shall mean the Company’s Series A Stock, Series B Stock, Series C Stock
and Series C-l Stock held from time to time by the Investors listed on Exhibit A hereto and their permitted assigns. 
 (n) “Special Registration Statement” shall mean (i) a registration statement relating to any employee benefit plan or (ii) with respect to any corporate
reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt
securities. 
 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 

2.1 Restrictions on Transfer. 

(a) Each Holder agrees not to make any disposition of all or any portion of the Shares or Registrable Securities
unless and until: 
 (i) there is then in effect a registration statement under the Securities Act
covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (ii) (A) The transferee has agreed in writing to be bound by the terms of Section 2.1 of this Agreement, (B) such Holder shall have notified the Company of the proposed disposition
and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel,
reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act; provided that it is agreed that the Company will not require opinions of counsel for transactions made
pursuant to Rule 144, except in unusual circumstances. After its Initial Offering, the Company will not require any transferee pursuant to Rule 144 to be bound by the terms of this Agreement if the shares so transferred do not remain Registrable
Securities following such transfer. 
 (b) Notwithstanding the provisions of subsection (a) above,
no such restriction shall apply to a transfer by a Holder that is (A) a partnership or limited partnership transferring to its partners or former partners in accordance with partnership interests, (B) a corporation

  
 3 

 
transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (C) a limited liability company transferring to its members or former
members in accordance with their interest in the limited liability company, or (D) an individual transferring to the Holder’s family member or trust for the benefit of an individual Holder; provided that in each case the
transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 
 (c) Each certificate representing Shares or Registrable Securities shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required
under applicable state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE,
PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (d) The Company shall
be obligated to reissue promptly unlegended certificates at the request of any Holder thereof if (i) the Company has completed its Initial Offering and (ii) the Holder shall have obtained an opinion of counsel (which counsel may be counsel
to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend; provided that the second legend
listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions under this Section 2.1. 
 (e) Any legend endorsed on an instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company
of an order of the appropriate blue sky authority authorizing such removal. 
 2.2 Demand Registration.

 (a) Subject to the conditions of this Section 2.2, if the Company shall receive a written
request from the Holders of at least 30% of the Registrable Securities then outstanding 

  
 4 

 
(the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the registration of Registrable Securities, provided that the
anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $5,000,000 (a “Qualified Public Offering”), then the Company shall, within 30 days of the receipt thereof, give written notice
of such request to all Holders, and subject to the limitations of this Section 2.2, effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be
registered. 
 (b) If the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.2, and the Company shall include such information in the written notice referred to in Section 2.2(a).
In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the
underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting by the Holders of a majority of the Registrable Securities held by all Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 2.2,
if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities that would
otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities
held by all such Holders (including the Initiating Holders); provided, however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all
other securities of the Company are first entirely excluded from the underwriting and registration. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c) The Company shall not be required to effect a registration pursuant to this Section 2.2: 

(i) prior to the earlier of (A) June 30, 2012 and (B) the expiration of the restrictions on
transfer set forth in Section 2.11 following the Initial Offering; 
 (ii) after the Company has
effected two registrations pursuant to this Section 2.2, and such registrations have been declared or ordered effective; 
 (iii) during the period starting with the date of filing of, and ending on the date 180 days (or such longer period as may be determined pursuant to Section 2.11 hereof) following the
effective date of the registration statement pertaining to a public offering, other than pursuant to a Special Registration Statement; provided that the Company makes reasonable good faith efforts to cause such registration statement
to promptly become effective; 

  
 5 

 (iv) if within 30 days of receipt of a written request from
Initiating Holders pursuant to Section 2.2(a), the Company gives notice to the Holders of the Company’s intention to file a registration statement for a public offering, other than pursuant to a Special Registration Statement, within 90
days; 
 (v) if the Company shall furnish to Holders requesting a registration statement pursuant to
this Section 2.2 a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its
stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than 90 days after receipt of the request of the Initiating Holders;
provided that such right to delay a request shall be exercised by the Company not more than once in any 12 month period and provided further that the Company shall not register any securities for the account of itself or any other
stockholder during such 90 day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Securities
Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common
Stock being registered is issuable upon conversion of debt securities that are also being registered); 

(vi) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 2.4 below; or 
 (vii) in any
particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

2.3 Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at least 15
days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of
the Company, but excluding Special Registration Statements) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder. Each Holder desiring to include in
any such registration statement all or any part of the Registrable Securities held by it shall, within 15 days after the above-described notice from the Company, so notify the Company in writing. Such notice shall state the intended method of
disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right
to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 

(a) Underwriting. If the registration statement of which the Company gives notice under this Section 2.3 is
for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include 

  
 6 

 
Registrable Securities in a registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten,
the number of shares that may be included in the underwriting shall be allocated, first, to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any
stockholder of the Company (other than a Holder) on a pro rata basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below 30% of the total amount of
securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be
excluded in accordance with the immediately preceding clause. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least 10
business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited
liability company or corporation, the partners, retired partners, members, retired members, stockholders and affiliates of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any
trusts for the benefit of any of the foregoing person shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying
registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 
 (b) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 whether or not any Holder has elected to
include securities in such registration, and shall promptly notify any Holder that has elected to include shares in such registration of such termination or withdrawal. The Registration Expenses of such withdrawn registration shall be borne by the
Company in accordance with Section 2.5 hereof. 
 2.4 Form S-3 Registration. In case the Company
shall receive from any Holder or Holders of at least 10% of the Registrable Securities then outstanding a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form
registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all
other Holders of Registrable Securities; and 
 (b) as soon as practicable, effect such registration and
all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and 

  
 7 

 
distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities
of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided, however, that the Company shall not
be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i) if Form S-3 is not available for such offering by the Holders; 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in
such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $500,000; 
 (iii) if within 30 days of receipt of a written request from any Holder or Holders pursuant to this Section 2.4, the Company gives notice to such Holder or Holders of the Company’s
intention to make a public offering within 90 days, other than pursuant to a Special Registration Statement; 

(iv) if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board of Directors
of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in which event the
Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than 90 days after receipt of the request of the Holder or Holders under this Section 2.4; provided, that such right
to delay a request shall be exercised by the Company not more than once in any 12 month period and provided further that the Company shall not register any securities for the account of itself or any other stockholder during
such 90 day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Securities Act, a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being
registered is issuable upon conversion of debt securities that are also being registered); 
 (v) if the
Company has, within the 12-month period preceding the date of such request, already effected two registrations on Form S-3 for the Holders pursuant to this Section 2.4; or 

(vi) in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c) Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the Registrable
Securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for registration or registrations effected
pursuant to Section 2.2. 

  
 8 

 
All Registration Expenses incurred in connection with registrations requested pursuant to this Section 2.4 shall be paid by the Company. 

(d) If the Holders intend to distribute the Registrable Securities covered by their request pursuant this
Section 2.4 by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.4 and the Company shall include such information in the written notice referred to in Section 2.4(a).
In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the
underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting by the Holders of a majority of the Registrable Securities proposed to be distributed through such underwriting (which underwriter or underwriters shall be reasonably acceptable to the Company). Notwithstanding any other provision of
this Section 2.4, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable
Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of
Registrable Securities held by all such Holders; provided, however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities
of the Company are first entirely excluded from the underwriting and registration. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

2.5 Expenses of Registration. Except as otherwise specifically provided herein, all Registration Expenses incurred
in connection with any registration, qualification or compliance pursuant to Section 2.2, 2.3 or 2.4 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations hereunder, shall be borne by the
holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay for expenses of any registration proceeding begun pursuant to Section 2.2 or 2.4, the
request of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning the Company of which the Initiating Holders were not aware at the time of such request or
(b) the Holders of a majority of Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be obligated pursuant to Section 2.2(c)
or 2.4(b)(v), as applicable, to undertake any subsequent registration, in which event such right shall be forfeited by all Holders). If the Holders are expressly required to pay any Registration Expenses under the terms of this Agreement, such
Registration Expenses shall be borne by the holders of securities (including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the
Registration Expenses of a withdrawn offering pursuant to clause (a) above, then such registration shall not be deemed to have been effected for purposes of determining whether the Company shall be obligated pursuant to Sections 2.2(c) or
2.4(b)(v), as applicable, to undertake any subsequent registration. 

  
 9 

 2.6 Obligations of the Company. Whenever required to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all
reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to 60 days or, if
earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that, subject to terms of this Agreement, at any time, upon written notice to the participating Holders and for a
period not to exceed 60 days thereafter (the “Suspension Period”), the Company may delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the
Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that there is or may be in existence material nonpublic
information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below); provided however, that
notwithstanding the foregoing, the Company may not exercise its foregoing right to delay or suspend a registration statement more than once in any 12 month period. In the event that the Company shall exercise its right to delay or suspend the filing
or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the
Suspension Period for an additional consecutive 60 days with the consent of the holders of 60% of the Registrable Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld. If so directed by
the Company, all Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after
receiving notice of such delay or suspension; and (ii) use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus
relating to such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file, cause to become effective or maintain the effectiveness of any registration statement
other than a registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth
in subsection (a) above. 
 (c) Furnish to the Holders such number of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

  
 10 

 (d) Use its reasonable efforts to register and qualify the securities
covered by such registration statement under such other securities or blue sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such
offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
 (f) Promptly notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act
of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company shall use reasonable efforts to promptly amend or supplement such prospectus in order to cause such prospectus not to include any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

(g) Use its reasonable efforts to furnish, on the date that such Registrable Securities are delivered to the
underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given
to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given
by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 
 2.7 Delay of Registration; Furnishing Information. 

(a) No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 (b) It shall be a condition precedent to the obligations of the Company to take any action pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such
information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to effect the registration of their Registrable Securities. 

(c) The Company shall have no obligation with respect to any registration requested pursuant to Section 2.2
or Section 2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price
required to 

  
 11 

 
originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under
Sections 2.2, 2.3 or 2.4: 
 (a) To the extent permitted by law, the Company will indemnify and hold
harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) and expenses to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (individually and collectively a “Violation”) by the Company:
(i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration
statement; and the Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such
loss, claim, damage, liability or action; provided however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld or delayed, nor shall the Company be liable in any such case to a Holder for any such loss, claim, damage, liability or action
to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, or a partner, member, officer,
director, underwriter or controlling person of such Holder. 
 (b) To the extent permitted by law, each
Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification, or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and
each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors or officers or
any person who controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or
controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based
upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any

  
 12 

 
preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the
extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in
connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or
controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; provided, however,
that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent
shall not be unreasonably withheld; provided further, that in no event shall any indemnity provided by a Holder under this Section 2.8 exceed the net proceeds from the offering received by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of
any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to the indemnifying party a written notice of the
commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying party, if representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The
failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent
prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.

 (d) If the indemnification provided for in this Section 2.8 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent
permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the
one hand and of the indemnified party on the other hand in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of
the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to

  
 13 

 
state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission; provided, that in no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder nor shall any Holder be obligated
to make any contribution under this Section 2.8(d) if such Holder has not committed a Holder Violation. 

(e) The obligations of the Company and Holders under this Section 2.8 shall survive completion of any
offering of Registrable Securities in a registration statement and, with respect to liability arising from an offering to which this Section 2.8 would apply that is covered by a registration filed before termination of this Agreement, such
termination. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 
 2.9 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of
Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member or other affiliate of a Holder that is a
corporation, partnership, limited partnership or limited liability company, (b) is a Holder’s family member or trust for the benefit of an individual Holder, or (c) acquires at least 500,000 shares of Registrable Securities (as
adjusted for stock splits and combinations) or all of the Registrable Securities of the transferring Holder; provided, however, (i) the transferor shall, within 10 days after such transfer, furnish to the
Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth
in this Agreement. 
 2.10 Limitation on Subsequent Registration Rights. Other than as provided in
Section 5.10, after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of
the Company’s capital stock, or to include such shares in a registration statement that would reduce the number of shares includable by the Holders. 

2.11 “Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall not sell, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder (other than those
included in the registration) during the 180-day period following the effective date of the Initial Offering (or such longer period as the underwriters or the Company shall in good faith request in order to facilitate compliance with NASD Rule 2711)
(the “Stand-off Period”), provided, that, all officers and directors of the Company are bound by and have entered into similar agreements. The obligations described in this Section 2.11 shall
not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar registration statement forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or

  
 14 

 
similar registration statement forms that may be promulgated in the future. The underwriters in connection with the offering are intended third-party beneficiaries of this Section 2.11 and
shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto, provided, however, that such right, power, and authority shall be subject to any amendment or waiver of this
Section 2.11 pursuant to the terms of Section 5.5 hereof. Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the Holder’s
obligations under Section 2.11 or that are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until
the end of said Stand-off Period. 
 2.12 Agreement to Furnish Information. If requested by the Company
or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within 10 days of such request, such information as may be required by the Company or such representative in connection with
the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act in which Registrable Securities are entitled to be registered under this Agreement. The obligations described
in Section 2.11 and this Section 2.12 shall not apply to a Special Registration Statement. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the
Company’s stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

2.13 Rule 144 Reporting. With a view to making available to the Holders the benefits of certain rules and
regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in SEC Rule 144 or any
similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b) File with the SEC, in a timely manner, all reports and other documents required of the Company under the
Exchange Act; and 
 (c) So long as a Holder owns any Registrable Securities, furnish to such Holder
forthwith upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements);
a copy of the most recent annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing
it to sell any such securities without registration. 
 2.14 Termination of Registration Rights. The
right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.2, Section 2.3, or Section 2.4 hereof shall terminate upon the earlier of: (i) the date five years
following an initial public offering of the Company’s Common Stock registered under the 

  
 15 

 
Securities Act that results in the conversion of all outstanding shares of Preferred Stock; (ii) such time as all Registrable Securities of the Company issuable or issued upon conversion of
the Shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during any 90 day period; or (iii) upon an “Acquisition” or “Asset Transfer”, each as defined
in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time. Upon such termination, such shares shall cease to be “Registrable Securities” hereunder for all purposes. 

SECTION 3. COVENANTS OF THE COMPANY. 
 3.1 Basic Financial Information and Reporting. 
 (a)
The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted
accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof), and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles
consistently applied. 
 (b) A “Major Investor” means an Investor who (together
with any shareholder(s) affiliated with such Investor) holds at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends, recapitalizations and the like) of Registrable Securities (whether
held directly or by the ownership of Shares that are convertible into Registrable Securities). As soon as practicable after the end of each fiscal year of the Company, and in any event within 120 days thereafter, or such longer period as approved by
the Board of Directors of the Company including all the Preferred Directors, the Company will furnish each Major Investor a balance sheet of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of
the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof) and setting forth in each case in comparative form the
figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion thereon by independent public accountants selected by the Company’s Board of Directors. 

(c) The Company will furnish to each Major Investor, as soon as practicable after the end of the first, second and
third quarterly accounting periods in each fiscal year of the Company, and in any event within 45 days thereafter, a balance sheet of the Company as of the end of each such quarterly period, and a statement of income and a statement of cash flows of
the Company for such quarterly period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof), with the
exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 
 (d) The Company will furnish to each Major Investor: (i) at least 30 days after the beginning of each fiscal year, an annual budget and operating plan for such fiscal year (and as soon as
available, any subsequent written revisions thereto); and (ii) as soon as practicable after the end of each month, and in any event within 30 days thereafter, a balance sheet of the 

  
 16 

 
Company as of the end of each such month, and a statement of income and a statement of cash flows of the Company for such month and for the current fiscal year to date, including a comparison to
annual budget and operating plan figures for such period, prepared in accordance with generally accepted accounting principles consistently applied across periods (except as noted thereon), with the exception that no notes need be attached to such
statements and year-end audit adjustments may not have been made. 
 3.2 Inspection Rights. Each Major
Investor shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such
information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to any Major Investor who is
a competitor of the Company, as determined in good faith by the Board of Directors of the Company, or with respect to information which the Board of Directors of the Company determines in good faith is confidential (unless such Major Investor is
then presently obligated under a non-disclosure or similar agreement with the Company that applies to such confidential information) or, upon advice of counsel, attorney-client privileged and should not, therefore, be disclosed. 

3.3 Reservation of Common Stock. The Company will at all times reserve and keep available, solely for issuance and
delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 
 3.4 Board Matters. 
 (a) So long as TPG
Biotechnology Partners III, L.P. (“TPG”) and/or any person or entity affiliated with TPG together own at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends,
recapitalizations and the like) of Registrable Securities, the Company shall cause the member of the Company’s Board of Directors who is designated by TPG, or who TPG has a right to elect (whether under any agreement or under the Company’s
Amended and Restated Certificate of Incorporation or Bylaws), to be a member of each committee of the Company’s Board of Directors, including without limitation the Audit Committee and Compensation Committee, if any, unless such right is waived
by the Board of Directors of the Company including all the Preferred Directors. 
 (b) So long as Mohr
Davidow Ventures (“MDV”) and/or any person or entity affiliated with MDV together own at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends, recapitalizations
and the like) of Registrable Securities, the Company shall cause the member of the Company’s Board of Directors who is designated by MDV, or who MDV has a right to elect (whether under any agreement or under the Company’s Amended and
Restated Certificate of Incorporation or Bylaws), to be a member of each committee of the Company’s Board of Directors, including without limitation the Audit Committee and Compensation Committee, if any, unless such right is waived by the
Board of Directors of the Company including all the Preferred Directors. 
 (c) So long as Alloy Ventures
(“Alloy”) and/or any person or entity affiliated with Alloy together own at least 500,000 shares (such number of shares to be proportionally 

  
 17 

 
adjusted to reflect stock splits, stock dividends, recapitalizations and the like) of Registrable Securities, the Company shall cause the member of the Company’s Board of Directors who is
designated by Alloy, or who Alloy has a right to elect (whether under any agreement or under the Company’s Amended and Restated Certificate of Incorporation or Bylaws), to be a member of each committee of the Company’s Board of Directors,
including without limitation the Audit Committee and Compensation Committee, if any, unless such right is waived by the Board of Directors of the Company including all the Preferred Directors. 

(d) So long as WM Organic Growth, Inc. (“WM”) and/or any person or entity affiliated with
WM together own at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends, recapitalizations and the like) of Registrable Securities, the Company shall (a) permit one representative of
WM to attend all meetings of the Company’s Board of Directors in a non-voting observer capacity and (b) give such representative copies of all notices, minutes, consents and other materials that the Company provides to its directors at the
same time that it provides such materials to such directors; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if (i) the Board of Director of
the Company determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, or to protect highly confidential proprietary information (unless WM is then presently obligated
under a non-disclosure or similar agreement with the Company that applies to such confidential information) or (ii) to enable the Board of Directors of the Company (or any committee thereof) to in good faith discuss matters relating to
agreements and the business relationship between the Company and WM for reasonable portions of a meeting; provided, further, that WM acknowledges and agrees that the confidentiality obligations applicable to WM related to the
Company’s confidential information set forth in that certain Joint Development Agreement, dated December 10, 2010, by and between the Company and WM, shall apply to all confidential information disclosed to WM pursuant to this
Section 3.4(d). 
 (e) So long as Mitsubishi Chemical Corporation
(“Mitsubishi”) and/or any person or entity affiliated with Mitsubishi together own at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends, recapitalizations and
the like) of Registrable Securities, the Company shall give Mitsubishi copies of all notices, minutes, consents and other materials that the Company provides to its directors at the same time that it provides such materials to such directors;
provided, however, that the Company reserves the right to exclude Mitsubishi from access to any material if the Company believes, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege,
to protect highly confidential proprietary information or for other similar reasons; provided, further, that Mitsubishi agrees to use the same degree of care as Mitsubishi uses to protect its own confidential information to keep
confidential any information furnished pursuant to this Section 3.4(e) to Mitsubishi that the Company identifies as being confidential or proprietary (so long as such information is not in the public domain), except that Mitsubishi may disclose
such proprietary or confidential information (i) to any partner, member, subsidiary, parent, officer or director of Mitsubishi; (ii) any attorney, accountant, consultant or other professional to the extent necessary for such person to
provide services in connection with monitoring Mitsubishi’s investment in the Company and/or enforcing Mitsubishi’s rights under the Purchase Agreement or any of the Related Agreements (as defined in the Purchase Agreement); (iii) at
such time as it 

  
 18 

 
enters the public domain through no fault of such representative or Mitsubishi; (iv) that is communicated to Mitsubishi free of any obligation of confidentiality; or (v) as required by
applicable law; provided, that in the case of clauses (i) and (ii), the recipient is advised of and agrees or has agreed to be bound by the confidentiality provisions of this paragraph or comparable restrictions. 

3.5 Option Pool. At the time of any Additional Closing (as defined in the Purchase Agreement), the Company and the
Investors shall use commercially reasonable efforts to effect an amendment of the Company’s 2008 Equity Incentive Plan (the “Plan”) such that the aggregate number of shares of the Company’s Common Stock subject to
outstanding stock options granted pursuant to the Plan and reserved for future issuance under the Plan shall equal approximately 15% of the total number of shares of capital stock of the Company on a fully diluted basis (taking into account the
exercise or conversion in full of all then outstanding warrants, options or rights to acquire capital stock) following each such Additional Closing. 
 3.6 Director Expenses. The Company shall reimburse the directors for all reasonable out-of-pocket expenses incurred by such directors for travel to and attendance at meetings of the Company’s
Board of Directors or any committee thereof and for expenses reasonably required for performing their duties as directors. Additionally, the Company will be responsible for the expenses associated with any observer selected by TPG, MDV, Alloy,
Draper Fisher Jurvetson (and/or any person or entity affiliated with Draper Fisher Jurvetson) or WM attending meetings of the Company’s Board of Directors or any committee thereof. 

3.7 Termination of Covenants. All covenants of the Company contained in Section 3 of this Agreement shall
expire and terminate as to each Investor upon the earlier of (i) such time as the Company becomes subject to the reporting provisions of the Exchange Act, or (ii) the consummation of an Acquisition or Asset Transfer, each as defined in the
Company’s Amended and Restated Certificate of Incorporation, as amended from time to time. 
 SECTION 4. RIGHTS OF FIRST REFUSAL.

 4.1 Subsequent Offerings. Subject to applicable securities laws, each holder of at least an
aggregate of 500,000 shares of Series C Stock or Series C-l Stock (such number of shares being subject to proportional adjustment to reflect stock splits, stock dividends, recapitalizations and the like with respect to the Series C Stock or Series
C-l Stock), and any of such holder’s affiliated funds (each, a “Major Series C Investor”), shall have a right of first refusal to purchase its pro rata share of all Equity Securities, as defined below, that the
Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity Securities excluded by Section 4.6 hereof. With respect to each issuance of Equity Securities, each Major Series C Investor’s
“pro rata share” will be determined immediately prior to the issuance of such Equity Securities and be equal to the ratio of: (a) the sum of (i) the number of outstanding shares of Common Stock then held by such
Major Series C Investor that were issued upon the conversion of shares of the Series B Stock, Series C Stock and/or Series C-l Stock plus (ii) the number of shares of Common Stock then issuable upon the conversion of all outstanding shares of
the Series B Stock, Series C Stock and/or Series C-l Stock then held by such Major Series C Investor plus (iii) the number of shares of Common Stock ultimately issuable upon the exercise or conversion in full of all then outstanding warrants,

  
 19 

 
options or rights to acquire stock then held by such Major Series C Investor (other than, in the case of such rights to acquire, shares of Common Stock described in the preceding
clause (ii)); to (b) the sum of (i) the total number of shares of the Company’s outstanding Common Stock plus (ii) the total number of shares of Common Stock issuable upon conversion of outstanding shares of Series B Stock,
Series C Stock and Series C-l Stock plus (iii) the total number of shares of Common Stock issuable upon the exercise of any outstanding warrants or options, in each case immediately prior to the issuance of the Equity Securities. The term
“Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common
Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security or
(iv) any such warrant or right. 
 4.2 Exercise of Rights. If the Company proposes to issue any
Equity Securities, it shall give each Major Series C Investor written notice of its intention (the “Offer Notice”), describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to
issue the same. Each Major Series C Investor shall have 15 days from the giving of such notice to agree to purchase up to its pro rata share of the Equity Securities for the price and upon the terms and conditions specified in the notice by
giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Major Series C Investor who
would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale. If any Major Series C Investor fails to so agree within such 15 day period to purchase such Major Series C Investor’s full pro
rata share of an offering of Equity Securities (a “Non-Full Purchasing Investor”), then such Non-Full Purchasing Investor shall forfeit the right hereunder to purchase that part of his, her or its pro rata share of
such Equity Securities that such Non-Full Purchasing Investor did not so agree to purchase and the Company shall promptly give each Major Series C Investor who has timely agreed to purchase such Major Series C Investor’s full pro rata
share of such offering of Equity Securities (a “Full Purchasing Investor”) written notice of the failure of any Non-Full Purchasing Investor(s) to purchase such Non-Full Purchasing Investor’s full pro rata share
of such offering of Equity Securities (the “Overallotment Notice”). Each Full Purchasing Investor shall have a right of overallotment, such that such Full Purchasing Investor shall have the right, at his, her or its
option, to agree to purchase a portion of the Non-Full Purchasing Investors’ unpurchased pro rata shares of such offering on a pro rata basis according to the relative pro rata shares of the Full Purchasing Investors, at any time
within five days after receiving the Overallotment Notice. 
 4.3 Issuance of Equity Securities to Other
Persons. The Company shall have 90 days after the date on which it first gives an Offer Notice to a Major Series C Investor to sell the Equity Securities that were the subject to the Offer Notice and in respect of which the Major Series C
Investor’s rights under Section 4.2 were not exercised, at a price not lower and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the Company’s notice to the Major Series C
Investors pursuant to Section 4.2 hereof. If the Company has not sold such Equity Securities within 90 days of the date on which it first gives the Offer Notice to Major Series C Investors as provided pursuant to Section 4.2, then the

  
 20 

 
Company shall not thereafter issue or sell any Equity Securities, without first again offering such securities to the Major Series C Investors in the manner provided above. 

4.4 Termination and Waiver of Rights of First Refusal. The rights of first refusal established by this
Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to the Company’s Initial Offering (provided that in connection with such Initial Offering all
outstanding shares of Preferred Stock are converted to Common Stock) or (ii) an Acquisition or Asset Transfer (each as defined in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time).
Notwithstanding Section 5.5 hereof, the rights of first refusal established by this Section 4 may be amended, or any provision waived with and only with the written consent of the Company and the Major Series C Investors holding a majority
of the Registrable Securities held by all Major Series C Investors. 
 4.5 Assignment of Rights of First
Refusal. The rights of first refusal of each Major Series C Investor under this Section 4 may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.9. 

4.6 Excluded Securities. Notwithstanding the foregoing, the rights of first refusal established by this
Section 4 shall have no application to any of the following Equity Securities: 
 (a) up to
11,421,529 shares (or such larger number as may be approved by the Board of Directors of the Company including all the Preferred Directors) of Common Stock and/or options, warrants or other Common Stock purchase rights and the Common Stock issued
pursuant to such options, warrant or other rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) issued or granted to employees, officers or directors of, or consultants or advisors to the Company or any
subsidiary pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board of Directors of the Company; provided, however, that such amount shall be increased to reflect any shares of
Common Stock (i) not issued pursuant to the rights, options or warrants described above in this clause (a) (“Unexercised Options”) as a result of the termination of such Unexercised Options or (ii) reacquired
by the Company from employees, directors or consultants pursuant to arrangements approved by the Company’s Board of Directors that permit the Company to repurchase such shares upon termination of such persons’ services to the Company;

 (b) stock issued or issuable pursuant to any rights or agreements, options, warrants or convertible
securities outstanding as of the date of this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first refusal established by this Section 4 were complied
with, waived, or were inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the Company of such rights or agreements; 

(c) any Equity Securities issued pursuant to a bona fide merger, consolidation, acquisition or similar business
combination the terms of which are approved by the Board of Directors, with and including the approval of all the Preferred Directors, provided that such Equity Securities are not issued to strategic investors who are not Investors and
not stockholders of the Company as of the date of this Agreement; 

  
 21 

 (d) any Equity Securities issued in connection with any stock split,
stock dividend or recapitalization by the Company 
 (e) any Equity Securities issued pursuant to any
equipment or real estate leasing arrangement, or any debt financing from a bank or similar financial institution and with a federal or state charter approved by the Board of Directors of the Company, with and including the approval of all the
Preferred Directors; 
 (f) any Equity Securities that are issued by the Company pursuant to an effective
registration statement filed under the Securities Act for a Qualified Public Offering; 
 (g) any Equity
Securities issued in connection with strategic transactions involving the Company and other entities for the purpose of (x) joint venture, manufacturing, marketing or distribution arrangements, (y) technology transfer, collaboration,
licensing or development arrangements and (z) any other arrangements involving corporate partners that are primarily for purposes other than raising capital; provided that in each case such strategic transactions and the related
issuance of Equity Securities have been approved by the Board of Directors of the Company, with and including the approval of all the Preferred Directors; and 
 (h) any Equity Securities issued pursuant to the Purchase Agreement. 
 SECTION 5.
MISCELLANEOUS. 
 5.1 Governing Law. This Agreement shall be governed by and construed under the laws
of the State of California in all respects as such laws are applied to agreements among California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof. The parties agree
that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby submit to the
jurisdiction and venue of, any state or federal court located in the County of San Diego, California solely for purposes of disputes arising under this Agreement. 

5.2 Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable
Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the
Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of record of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3 Entire Agreement. This Agreement, the Exhibits and Schedules hereto, the Purchase Agreement and the
other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subject matter hereof and supersedes and entirely replaces the Prior Agreement, which is hereby terminated
by this Agreement and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth

  
 22 

 
herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement.

 5.4 Severability. In the event one or more of the provisions of this Agreement should, for any reason,
be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained herein. 
 5.5 Amendment and Waiver. 

(a) Except as otherwise expressly provided, this Agreement may be amended or modified, and the obligations of the
Company and the rights of the Holders under this Agreement may be waived, only upon the written consent of (i) the Company, (ii) the holders of at least a majority of the Registrable Securities then outstanding, (iii) the holders of
at least a majority of the Series B Stock included in the Registrable Securities then outstanding, (iv) the holders of at least a majority of the Series C Stock included in the Registrable Securities then outstanding and (v) the holders of
at least a majority of the Series C-l Stock included in the Registrable Securities then outstanding; provided, however, that any amendment or modification to this Agreement or waiver of any term of this Agreement that is not applied to
all Investors in the same manner on its face and that adversely affects the rights of an Investor hereunder in any material respect in a manner different and more adversely than all other Investors shall not be effective as to such Investor without
such Investor’s written consent; provided further, for all purposes of this Section and the foregoing proviso it is acknowledged and agreed that the addition of a new party to this Agreement as an “Investor” hereunder,
and/or the inclusion of additional classes or series of stock of the Company as Registrable Securities shall not, in and of itself, be deemed to adversely affect the rights of any Investor. 

(b) For the purposes of determining the number of Holders or Investors entitled to vote or exercise any rights
hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company. 
 5.6 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this
Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It
is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of
this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative.

 5.7 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (c) one day after deposit with a nationally
recognized overnight courier, specifying next day 

  
 23 

 
delivery, with written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at
such other address as such party may designate by 10 days advance written notice to the other parties hereto. 

5.8 Attorneys’ Fees. In the event that any suit or action is instituted under or in relation to this
Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party
under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 

5.9 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of
reference only and are not to be considered in construing this Agreement. 
 5.10 Additional Investors.
Notwithstanding anything to the contrary contained herein, if the Company shall issue additional shares of its Series C-l Stock pursuant to the Purchase Agreement, any purchaser of such shares of Series C-l Stock shall become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. Notwithstanding anything to the
contrary contained herein, if the Company shall issue Equity Securities in accordance with Section 4 of this Agreement, any acquirer of such Equity Securities may become a party to this Agreement by executing and delivering an additional
counterpart signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. 

5.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an
original, but all of which together shall constitute one instrument. 
 5.12 Aggregation of Stock. All
shares of Registrable Securities held or acquired by affiliated entities or persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this
Agreement. 
 5.13 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed
to refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 
 5.14 Termination. This Agreement shall terminate and be of no further force or effect upon the earlier of (i) an “Acquisition” or “Asset
Transfer” as such terms are defined in the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time; or (ii) the date five years following the closing of a firmly underwritten public offering
pursuant to an effective registration statement under the Securities Act, covering the offer and sale of Common Stock for the account of the Company in which (i) the per share price is at least $5.00 (such per share price, as adjusted for stock
splits, combinations, dividends, recapitalizations and the like), and (ii) the gross cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least $50,000,000. 

  
 24 

 [THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 25 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT as of the date set forth in the first paragraph hereof. 
  

			
	GENOMATICA, INC.
		
	 By:
	 	       /s/ Christophe H. Schilling

		 	       Christophe H. Schilling, Ph.D.

		 	       President and Chief Executive Officer

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.
  By: TPG Biotechnology GenPar III, L.P., its General Partner
  By: TPG
Biotech Advisors III, LLC, its General Partner

  

			
	 By:
	 	   /s/ Jeffery D.
Ekberg

  

			
	 Name:
	 	   Jeffery D. Ekberg

		
	 Title:
	 	   Vice
President

  

			
	 Address:
	 	 c/o Texas Pacific Group

301 Commerce Street
 Suite 3300
 Fort Worth, TX 76102

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

 MDV VIII, L.P. 
 as nominee
for 
 MDV VIII, L.P., 
 MDV VIII
Leaders’ Fund, L.P., and 
 MDV ENF VIII, L.P. 

 

			
	 By:
	 	 Eighth MDV Partners, L.L.C.

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ JOSH GREEN

	 Name:
	 	 JOSH GREEN

	 Title:
	 	 GENERAL PARTNER

  

			
	 Address:
	 	 Mohr, Davidow Ventures

3000 Sand Hill Road
 Bldg. 3, Suite 290
 Menlo Park, CA 94025

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

 ALLOY VENTURES 2005, L.P. 
  

			
	 By:
	 	 Alloy Ventures 2005, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Craig C. Taylor

	 Name:
	 	 CRAIG C. TAYLOR

	 Title:
	 	 Managing Member

  

			
	 Address:
	 	 Alloy Ventures

400 Hamilton Avenue, 4th floor

Palo Alto, CA 94301

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

DRAPER FISHER JURVETSON FUND IX, L.P. 
  

			
	 By:
	 	 /s/ John
Fisher

			
	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Director

 DRAPER FISHER JURVETSON PARTNERS IX, LLC 

 

			
	 By:
	 	 /s/ John
Fisher

			
	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Member

 DRAPER ASSOCIATES, L.P. 
  

			
	 By:
	 	 /s/ Timothy C.
Draper

			
	 Name:
	 	 Timothy C. Draper

	 Title:
	 	 General Partner

  

			
	 Address:
	 	 Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

 WM ORGANIC GROWTH, INC. 
  

			
	 By:
	 	 /s/ Carl Rush

	 Name:
	 	 Carl Rush

	 Title:
	 	 President

  

			
	 Address:
	 	 WM Organic Growth, Inc.

1001 Fannin St., Suite 4000

Houston, TX 77002

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

 MITSUBISHI CHEMICAL CORPORATION 
  

			
	 By:
	 	 /s/ Toru Mori

	 Name:
	 	 Toru Mori

	 Title:
	 	 General Manager
 Petrochemicals R&D Division

  

			
	 Address:
	 	 14-1, Shiba 4-Chome, Minato-ku

Tokyo 108-0014, Japan

  
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
  

					
	 INVESTOR
	  	SHARES OF 
PREFERRED
STOCK	 
		
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.

c/o Texas Pacific Group
 301 Commerce Street, Suite 3300
 Fort Worth, TX 76102
	  	 	12,378,932	  
	 ICELAND GENOMIC VENTURES, S.A.

12 rue Gullaume Schuerder
 L 2924 Luxemburg
	  	 	3,500,000	  
		
	 MDV VIII, L.P.
 Mohr, Davidow Ventures
 3000 Sand Hill Road

Bldg. 3, Suite 290

Menlo Park, CA 94025
	  	 	10,417,232	  
		
	 ALLOY VENTURES 2005, L.P.

Alloy Ventures

400 Hamilton Avenue, 4th floor
 Palo Alto, CA 94301
	  	 	6,255,575	  
		
	 DRAPER FISHER JURVETSON FUND IX, L.P.

Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025
	  	 	3,940,751	  
		
	 DRAPER FISHER JURVETSON PARTNERS IX, LLC

Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025
	  	 	106,789	  
		
	 DRAPER ASSOCIATES, L.P.

Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025
	  	 	140,293	  
		
	 WM ORGANIC GROWTH, INC.

WM Organic Growth, Inc.
 1001 Fannin St., Suite 4000
 Houston, TX 77002
	  	 	4,483,209	  
		
	 MITSUBISHI CHEMICAL CORPORATION

General Manager, Mitsubishi Chemical Corporation
 Petrochemicals R&D Division
 14-1 Shiba 4-Chome, Minato-Ku

Tokyo 108-0014, Japan
	  	 	1,630,258	  

  
 A-1

 SCHEDULE OF INVESTORS 

					
	 INVESTOR
	  	SHARES OF 
PREFERRED
STOCK	 
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR UNIVERSITY (DAPER I)
 Stanford Management
Company
 2770 Sand Hill Road
 Menlo Park, CA 94025
 Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR UNIVERSITY (SEVF II)
 Stanford Management
Company
 2770 Sand Hill Road
 Menlo Park, CA 94025
 Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE UCLA FOUNDATION
 10920 Wilshire Blvd., Suite 900
 Los Angeles, CA 90024

Attn: Investment Coordinator
	  	 	16,703	  
		
	 CHRISTOPHER E. GANN
 14770 Caminito Barbuda
 Del Mar, CA 92014
	  	 	266,840	  
		  	  
	  
	 
		
	 TOTAL 
	  	 	43,169,988	  
		  	  
	  
	 

  
 A-2

 SCHEDULE OF INVESTORS 

 GENOMATICA, INC. 

FIRST AMENDMENT TO 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This
FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this
“Amendment”), amending the Amended and Restated Investor Rights Agreement by and among GENOMATICA, INC., a Delaware corporation (the “Company”) and the investors
listed on Exhibit A thereto (the “Investors”) dated as of December 10, 2010 (the “Investor Rights Agreement”), is entered into as of January 5, 2011 by and among the Company and certain of
the Investors. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Investor Rights Agreement. 
 RECITALS 
 WHEREAS, the Company and
the Investors have previously entered into the Investor Rights Agreement; 
 WHEREAS,
Section 5.5 of the Investor Rights Agreement provides that the Investor Rights Agreement may be amended with the written consent of the Company and (i) the holders of at least a majority of the Registrable Securities then outstanding,
(ii) the holders of at least a majority of the Series B Preferred Stock included in the Registrable Securities then outstanding, (iii) the holders of at least a majority of the Series C Preferred Stock included in the Registrable
Securities then outstanding and (iv) the holders of at least a majority of the Series C-1 Preferred Stock included in the Registrable Securities then outstanding (collectively, the “Required Holders”); and 

WHEREAS, the undersigned constitute the Company and the Required Holders. 

AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained herein and in the Investor Rights Agreement, and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1.
Section 2.1(b) of the Investor Rights Agreement. Section 2.1(b) of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 

“(b) Notwithstanding the provisions of subsection (a) above, no such restriction shall
apply to a transfer by a Holder that is (A) a partnership or limited partnership transferring to its partners or former partners in accordance with partnership interests, (B) a corporation or similar entity transferring to a wholly-owned
subsidiary or a parent corporation that owns all of the capital stock of the Holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, (D) an
individual transferring to the Holder’s family member or trust for the benefit of an individual Holder, or (E) transferring to any other entity who, directly or indirectly, controls, is controlled by, or is under common control with the
Holder, 

 
including without limitation any general partner, managing member, officer or director of the Holder or any venture capital fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, the Holder; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he
were an original Holder hereunder.” 
 2. Section 2.9 of the Investor Rights Agreement.
Section 2.9 of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 
 “2.9 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or
assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member, other affiliate (or any other entity
who, directly or indirectly, controls, is controlled by, or is under common control with the Holder) of a Holder that is a corporation, partnership, limited partnership, limited liability company or similar entity, (b) is a Holder’s family
member or trust for the benefit of an individual Holder, or (c) acquires at least 500,000 shares of Registrable Securities (as adjusted for stock splits and combinations) or all of the Registrable Securities of the transferring Holder;
provided, however, (i) the transferor shall, within 10 days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which
such registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement.” 
 3. Addition of Section 3.4(f) to the Investor Rights Agreement. A Section 3.4(f) shall be added to the Investor Rights Agreement and shall read in its entirety as follows: 

“(f) So long as Batios Holdings Limited (“Batios”)
and/or any person or entity affiliated with Batios together own at least 500,000 shares (such number of shares to be proportionally adjusted to reflect stock splits, stock dividends, recapitalizations and the like) of Registrable Securities, the
Company shall (a) permit one representative of Batios to attend all meetings of the Company’s Board of Directors in a non-voting observer capacity and (b) give such representative copies of all notices, minutes, consents and other
materials that the Company provides to its directors at the same time that it provides such materials to such directors; provided, however, that the Company reserves the right to exclude such representative from access to any material or
meeting or portion thereof if the Board of Directors of the Company determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege, or to protect highly confidential
proprietary information; provided, further, that such representative agrees to use the same degree of care as Batios uses to protect its own confidential information to keep confidential any information furnished pursuant to this
Section 3.4(f) to such representative that the Company identifies as being confidential or proprietary (so long as such 

 
information is not in the public domain), except that such representative may disclose such proprietary or confidential information (i) to any partner, member, subsidiary, parent, officer or
director of Batios; (ii) any attorney, accountant, consultant or other professional to the extent necessary for such person to provide services in connection with monitoring Batios’ investment in the Company and/or enforcing Batios’
rights under the Purchase Agreement or any of the Related Agreements (as defined in the Purchase Agreement); (iii) at such time as it enters the public domain through no fault of such representative or Batios; (iv) that is communicated to
such representative free of any obligation of confidentiality; or (v) as required by applicable law; provided, that in the case of clauses (i) and (ii), the recipient is advised of and agrees or has agreed to be bound by the
confidentiality provisions of this paragraph or comparable restrictions.” 
 4. Section 3.6 of the
Investor Rights Agreement. Section 3.6 of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 

“3.6 Director Expenses. The Company shall reimburse the directors for all reasonable
out-of-pocket expenses incurred by such directors for travel to and attendance at meetings of the Company’s Board of Directors or any committee thereof and for expenses reasonably required for performing their duties as directors. Additionally,
the Company will be responsible for the expenses associated with any observer selected by TPG, MDV, Alloy, Draper Fisher Jurvetson (and/or any person or entity affiliated with Draper Fisher Jurvetson), WM or Batios attending meetings of the
Company’s Board of Directors or any committee thereof.” 
 5. Section 4.6(a) of the Investor
Rights Agreement. Section 4.6(a) of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 
 “(a) up to 12,260,631 shares (or such larger number as may be approved by the Board of Directors of the Company including all the Preferred Directors) of Common Stock and/or options, warrants
or other Common Stock purchase rights and the Common Stock issued pursuant to such options, warrant or other rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) issued or granted to employees, officers
or directors of, or consultants or advisors to the Company or any subsidiary pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board of Directors of the Company; provided,
however, that such amount shall be increased to reflect any shares of Common Stock (i) not issued pursuant to the rights, options or warrants described above in this clause (a) (“Unexercised Options”)
as a result of the termination of such Unexercised Options or (ii) reacquired by the Company from employees, directors or consultants pursuant to arrangements approved by the Company’s Board of Directors that permit the Company to
repurchase such shares upon termination of such persons’ services to the Company;” 

 6. Exhibit A of the Investor Rights Agreement. Exhibit A of the
Investor Rights Agreement shall be amended and restated to read in its entirety as set forth on Exhibit A hereto. 
 7. Effect of Amendment. Except as expressly modified by this Amendment, the Investor Rights Agreement shall remain unmodified and in full force and effect. 

8. Governing Law. This Amendment shall be governed by and construed under the laws of the State of California in
all respects as such laws are applied to agreements among California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof. The parties agree that any action brought by
either party under or in relation to this Amendment, including without limitation to interpret or enforce any provision of this Amendment, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any
state or federal court located in the County of San Diego, California solely for purposes of disputes arising under this Amendment. 
 9. Counterparts. This Amendment may be executed in any number of counterparts and signatures delivered by facsimile, each of which shall be deemed an original, but all of which together shall
constitute one instrument. 
 10. Effectiveness. This Amendment shall be effective as of the closing of
the purchase by Batios Holdings Limited of an aggregate of 4,754,914 shares of the Company’s Series C-1 Preferred Stock in an Additional Closing (as defined in the Purchase Agreement). 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	COMPANY:
	
	GENOMATICA, INC.
		
	 By:
	 	 /s/ Christophe Schilling

		 	 Christophe Schilling, Ph.D.

		 	 President and Chief Executive Officer

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
 INVESTORS: 

TPG BIOTECHNOLOGY PARTNERS III, L.P. 
 By: TPG Biotechnology GenPar III, L.P., its General Partner 
 By: TPG Biotech
Advisors III, LLC, its General Partner 
  

			
	 By:
	 	 /s/ Jeff Ekberg

		
	 Name:
	 	 Jeff Ekberg

		
	 Title:
	 	 Vice President

  

			
	 Address:
	 	 c/o Texas Pacific Group

		 	 301 Commerce Street

		 	 Suite 3300

		 	 Fort Worth, TX 76102

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
 INVESTORS: 

MDV VIII, L.P. 
 as
nominee for 
 MDV VIII, L.P., 
 MDV VIII Leaders’ Fund, L.P., and 
 MDV ENF VIII, L.P. 

 

			
	 By:
	 	 Eighth MDV Partners, L.L.C.

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ JOSH GREEN

	 Name:
	 	 JOSH GREEN

	 Title:
	 	 GENERAL PARTNER

  

			
	 Address:
	 	 Mohr, Davidow Ventures

		 	 3000 Sand Hill Road

		 	 Bldg. 3, Suite 290

		 	 Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	 INVESTORS:
  

ALLOY VENTURES 2005, L.P.

		
	 By:
	 	 Alloy Ventures 2005, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ CRAIG C. TAYLOR

	 Name:
	 	 CRAIG C. TAYLOR

	 Title:
	 	 Managing Member

  

			
	 Address:
	 	 Alloy Ventures

		 	 400 Hamilton Avenue, 4th floor

		 	 Palo Alto, CA 94301

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	DRAPER FISHER JURVETSON FUND IX, L.P.
		
	 By:
	 	 /s/ John Fisher

	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Director

	
	DRAPER FISHER JURVETSON PARTNERS IX, LLC
		
	 By:
	 	 /s/ John Fisher

	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Member

	
	DRAPER ASSOCIATES, L.P.
		
	 By:
	 	 /s/ Timothy C. Draper

	 Name:
	 	 Timothy C. Draper

	 Title:
	 	 General Partner

  

			
	 Address:
	 	 Draper Fisher Jurvetson

		 	 2882 Sand Hill Road, Suite 150

		 	 Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	WM ORGANIC GROWTH, INC.
		
	 By:
	 	 /s/ Carl Rush

	 Name:
	 	 Carl Rush

	 Title:
	 	 President

  

			
	Address:	 	WM Organic Growth, Inc.
		 	 1001 Fannin St., Suite 4000

Houston, TX 77002

 IN WITNESS
WHEREOF, the parties have executed this FIRST AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	MITSUBISHI CHEMICAL CORPORATION
		
	 By:
	 	 /s/ Toru Mori

	 Name:
	 	 Toru Mori

	 Title:
	 	 General Manager

		 	 Petrochemicals R&D Division

  

			
	 Address:
	 	 14-1, Shiba 4-Chome, Minato-ku

		 	 Tokyo 108-0014, Japan

 EXHIBIT A 

SCHEDULE OF INVESTORS 
  

					
	 INVESTOR
	  	SHARES OF PREFERRED
STOCK	 
		
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.

c/o Texas Pacific Group

301 Commerce Street, Suite 3300

Fort Worth, TX 76102
	  	 	12,378,932	  
		
	 ICELAND GENOMIC VENTURES, S.A.

12 rue Gullaume Schuerder

L 2924 Luxemburg
	  	 	3,500,000	  
		
	 MDV VIII, L.P.
 Mohr, Davidow Ventures
 3000 Sand Hill Road

Bldg. 3, Suite 290

Menlo Park, CA 94025
	  	 	10,417,232	  
		
	 BATIOS HOLDINGS LIMITED

Trident Chambers, P.O. Box 146, Road Town,

Tortola, British Virgin Islands
	  	 	4,754,914	  
		
	 ALLOY VENTURES 2005, L.P.

Alloy Ventures
 400 Hamilton Avenue, 4th floor
 Palo Alto, CA 94301
	  	 	6,255,575	  
		
	 DRAPER FISHER JURVETSON FUND IX, L.P.

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	3,940,751	  
		
	 DRAPER FISHER JURVETSON PARTNERS IX, LLC

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	106,789	  
		
	 DRAPER ASSOCIATES, L.P.

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	140,293	  
		
	 WM ORGANIC GROWTH, INC.

WM Organic Growth, Inc.

1001 Fannin St., Suite 4000

Houston, TX 77002
	  	 	4,483,209	  
		
	 MITSUBISHI CHEMICAL CORPORATION

General Manager, Mitsubishi Chemical Corporation

Petrochemicals R&D Division

14-1 Shiba 4-Chome, Minato-Ku

Tokyo 108-0014, Japan
	  	 	1,630,258	  

					
	 INVESTOR
	  	SHARES OF PREFERRED
STOCK	 
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (DAPER I)

Stanford Management Company

2770 Sand Hill Road

Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (SEVF II)

Stanford Management Company

2770 Sand Hill Road

Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE UCLA FOUNDATION

10920 Wilshire Blvd., Suite 900

Los Angeles, CA 90024

Attn: Investment Coordinator
	  	 	16,703	  
		
	 CHRISTOPHER E. GANN

14770 Caminito Barbuda

Del Mar, CA 92014
	  	 	266,840	  
		
	TOTAL	  	 	47,924,902	  

 GENOMATICA, INC. 

SECOND AMENDMENT TO 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This
SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this
“Amendment”), amending the Amended and Restated Investor Rights Agreement by and among GENOMATICA, INC., a Delaware corporation (the “Company”) and the investors
listed on Exhibit A thereto (the “Investors”) dated as of December 10, 2010 and amended on January 5, 2011 (as amended, the “Investor Rights Agreement”), is entered into as of
February 22, 2011 by and among the Company and certain of the Investors. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Investor Rights Agreement. 

RECITALS 
 WHEREAS, the Company and the Investors have previously entered into the Investor Rights Agreement; 

WHEREAS, Section 5.5 of the Investor Rights Agreement provides that the
Investor Rights Agreement may be amended with the written consent of the Company and (i) the holders of at least a majority of the Registrable Securities then outstanding, (ii) the holders of at least a majority of the Series B Preferred
Stock included in the Registrable Securities then outstanding, (iii) the holders of at least a majority of the Series C Preferred Stock included in the Registrable Securities then outstanding and (iv) the holders of at least a majority of
the Series C-1 Preferred Stock included in the Registrable Securities then outstanding (collectively, the “Required Holders”); and 
 WHEREAS, the undersigned constitute the Company and the Required Holders. 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing and the promises and covenants contained herein and in the Investor Rights Agreement, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto agree as follows: 
 1. Defined Term. Each reference in
the Investor Rights Agreement to the “Purchase Agreement” shall refer to the Amended and Restated Series C-1 Preferred Stock Purchase Agreement dated as of the date hereof, by and among the Company and the purchasers listed on the Schedule
of Purchasers thereto, as the same may be amended from time to time (the “Purchase Agreement”). 
 2. Section 2.11 of the Investor Rights Agreement. Section 2.11 of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 

““Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall not sell,
transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect 

 
as a sale, any Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) during the 180-day period following the effective date of the
Initial Offering (or such longer period as the underwriters or the Company shall in good faith request in order to facilitate compliance with NASD Rule 2711) (the “Stand-off Period”), provided,
that, all officers and directors of the Company are bound by and have entered into similar agreements. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters
shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. The obligations described in this Section 2.11 shall not apply to a registration relating solely to employee benefit plans
on Form S-1 or Form S-8 or similar registration statement forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar registration statement forms that may be promulgated in the future. The
underwriters in connection with the offering are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto, provided,
however, that such right, power, and authority shall be subject to any amendment or waiver of this Section 2.11 pursuant to the terms of Section 5.5 hereof. Each Holder agrees to execute and deliver such other agreements as
may be reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. The Company may impose stop-transfer instructions with
respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said Stand-off Period.” 
 3. Section 3.4(g) of the Investor Rights Agreement. A new Section 3.4(g) of the Investor Rights Agreement is hereby added and shall read in its entirety as follows: 

“So long as VantagePoint Venture Partners 2006 (Q), L.P., a Delaware limited partnership, and VantagePoint CleanTech
Partners II, L.P., a Cayman Islands limited partnership (collectively “VPVP”) and/or any person or entity affiliated with VPVP together own at least 500,000 shares (such number of shares to be proportionately adjusted to reflect
stock splits, stock dividends, recapitalizations and the like) of Registrable Securities, the Company shall cause the member of the Company’s Board of Directors who is designated by VPVP, or who VPVP has a right to elect (whether under any
agreement or under the Company’s Amended and Restated Certificate of Incorporation or Bylaws), to be a member of each committee of the Company’s Board of Directors, including without limitation the Audit Committee and Compensation
Committee, if any, unless such right is waived by the Board of Directors of the Company including all the Preferred Directors.” 
 4. Section 3.6 of the Investor Rights Agreement. Section 3.6 of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 

 “3.6 Director Expenses. The Company shall reimburse the
directors for all reasonable out-of-pocket expenses incurred by such directors for travel to and attendance at meetings of the Company’s Board of Directors or any committee thereof and for expenses reasonably required for performing their
duties as directors. Additionally, the Company will be responsible for the expenses associated with any observer selected by TPG, MDV, Alloy, Draper Fisher Jurvetson (and/or any person or entity affiliated with Draper Fisher Jurvetson), WM, Batios
or VantagePoint Venture Partners (and/or any person or entity affiliated with VantagePoint Venture Partners) attending meetings of the Company’s Board of Directors or any committee thereof.” 

5. Section 3.7 and 3.8 of the Investor Rights Agreement. Section 3.7 of the Investor Rights Agreement is
hereby renumbered as “Section 3.8” and a new Section 3.7 is hereby added to read in its entirety as follows: 
 “3.7 Intellectual Property. The Company covenants to devote best efforts, within the 12-month period that begins on the Closing Date, to assess and take any actions necessary to minimize
potential intellectual property risks associated with genetic deletion strains used in its production of BDO.” 
 6. Section 4.6(a) of the Investor Rights Agreement. Section 4.6(a) of the Investor Rights Agreement is hereby amended and restated to read in its entirety as follows: 

“(a) up to 13,699,094 shares (or such larger number as may be approved by the Board of Directors of the
Company including all the Preferred Directors) of Common Stock and/or options, warrants or other Common Stock purchase rights and the Common Stock issued pursuant to such options, warrant or other rights (as adjusted for any stock dividends,
combinations, splits, recapitalizations and the like) issued or granted to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary pursuant to stock purchase or stock option plans or other arrangements that
are approved by the Board of Directors of the Company; provided, however, that such amount shall be increased to reflect any shares of Common Stock (i) not issued pursuant to the rights, options or warrants described
above in this clause (a) (“Unexercised Options”) as a result of the termination of such Unexercised Options or (ii) reacquired by the Company from employees, directors or consultants pursuant to arrangements
approved by the Company’s Board of Directors that permit the Company to repurchase such shares upon termination of such persons’ services to the Company;” 

7. Exhibit A of the Investor Rights Agreement. Exhibit A of the Investor Rights Agreement shall be amended and
restated to read in its entirety as set forth on Exhibit A hereto. 
 8. Effect of Amendment.
Except as expressly modified by this Amendment, the Investor Rights Agreement shall remain unmodified and in full force and effect. 
 9. Governing Law. This Amendment shall be governed by and construed under the laws of the State of California in all respects as such laws are applied to agreements among

 
California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof. The parties agree that any action brought by either
party under or in relation to this Amendment, including without limitation to interpret or enforce any provision of this Amendment, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or
federal court located in the County of San Diego, California solely for purposes of disputes arising under this Amendment. 
 10. Counterparts. This Amendment may be executed in any number of counterparts and signatures delivered by facsimile, each of which shall be deemed an original, but all of which together shall
constitute one instrument. 
 11. Effectiveness. This Amendment shall be effective as of the closing of
the purchase by VantagePoint Venture Partners 2006 (Q), L.P., a Delaware limited partnership, and VantagePoint CleanTech Partners II, L.P., a Cayman Islands limited partnership, of an aggregate of 7,607,870 shares of the Company’s Series C-1
Preferred Stock in the VPVP Closing (as defined in the Purchase Agreement). 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK] 

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	COMPANY:
	
	GENOMATICA, INC.
		
	 By:
	 	 /s/ Christophe Schilling

		 	 Christophe Schilling, Ph.D.

		 	 President and Chief Executive Officer

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
 INVESTORS: 

TPG BIOTECHNOLOGY PARTNERS III, L.P. 
 By: TPG Biotechnology GenPar III, L.P., its general partner 
 By: TPG Biotechnology
GenPar III Advisors, LLC, its general partner 
  

			
	 By:
	 	 /s/ Ronald Cami

		
	 Name:
	 	 Ronald Cami

		
	 Title:
	 	 Vice President

			
		
	 Address:
	 	 c/o Texas Pacific Group
 301 Commerce Street
 Suite 3300

Fort Worth, TX 76102

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	 MDV VIII, L.P.
 as nominee for
 MDV VIII, L.P.,

MDV VIII Leaders’ Fund, L.P., and
 MDV ENF VIII, L.P.

		
	 By:
	 	 Eighth MDV Partners, L.L.C.

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Josh Green

	 Name:
	 	 JOSH GREEN

	 Title:
	 	 GEN PARTNER

		
	 Address:
	 	 Mohr, Davidow Ventures
 3000 Sand Hill Road
 Bldg. 3, Suite 290

Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	ALLOY VENTURES 2005, L.P.
		
	 By:
	 	 Alloy Ventures 2005, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ Craig C. Taylor

	 Name:
	 	 CRAIG C. TAYLOR

	 Title:
	 	 Managing Member

		
	 Address:
	 	 Alloy Ventures
 400 Hamilton Avenue, 4th floor
 Palo Alto, CA 94301

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTOR:
	
	DRAPER FISHER JURVETSON FUND IX, L.P.
		
	 By:
	 	 /s/ John Fisher

	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Director

	
	DRAPER FISHER JURVETSON PARTNERS IX, LLC
		
	 By:
	 	 /s/ John Fisher

	 Name:
	 	 John Fisher

	 Title:
	 	 Managing Member

	
	DRAPER ASSOCIATES, L.P.
		
	 By:
	 	 /s/ Timothy C. Draper

	 Name:
	 	 Timothy C. Draper

	 Title:
	 	 General Partner

		
	 Address:
	 	 Drapper Fisher Jurvetson

		 	 2882 Sand Hill Road, Suite 150

		 	 Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	MITSUBISHI CHEMICAL CORPORATION
		
	 By:
	 	 /s/ Toru Mori

	 Name:
	 	 Toru Mori

	 Title:
	 	 General Manager

		 	 Petrochemicals R&D Division

		
	 Address:
	 	 14-1, Shiba 4-Chome, Minato-ku

		 	 Tokyo 108-0014, Japan

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	BATIOS HOLDINGS LIMITED
		
	 By:
	 	 /s/ Nataliya Zhmaylo Theocharous

	 Name:
	 	 Nataliya Zhmaylo Theocharous

	 Title:
	 	 Director

 IN WITNESS
WHEREOF, the parties have executed this SECOND AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	WM ORGANIC GROWTH, INC.
		
	 By:
	 	 /s/ Carl Rush

	 Name:
	 	 Carl Rush

	 Title:
	 	 President

		
	 Address:
	 	 WM Organic Growth, Inc.

		 	 1001 Fannin St., Suite 4000

		 	 Houston, TX 77002

 EXHIBIT A 

SCHEDULE OF INVESTORS 
  

					
	 INVESTOR
	 	SHARES OF 
PREFERRED
STOCK	 
		
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.

c/o Texas Pacific Group
 301 Commerce Street, Suite 3300
 Fort Worth, TX 76102
	 	 	12,378,932	  
		
	 ICELAND GENOMIC VENTURES, S.A.

12 rue Gullaume Schuerder
 L 2924 Luxemburg
	 	 	3,500,000	  
		
	 MDV VIII, L.P.
 Mohr, Davidow Ventures
 3000 Sand Hill Road

Bldg. 3, Suite 290

Menlo Park, CA 94025
	 	 	10,417,232	  
		
	 VANTAGEPOINT VENTURE PARTNERS 2006 (Q), L.P.

By: VantagePoint Venture Associates 2006, LLC
 1001 Bayhill Drive, Suite 300
 San Bruno, CA 94066
	 	 	3,803,935	  
		
	 VANTAGEPOINT CLEANTECH PARTNERS II, L.P.

By: VantagePoint CleanTech Associates II, L.P.
 By: VantagePoint Clean Tech Management, Ltd.
 1001 Bayhill Drive, Suite
300
 San Bruno, CA 94066
	 	 	3,803,935	  
		
	 BATIOS HOLDINGS LIMITED

Trident Chambers, P.O. Box 146, Road Town,
 Tortola, British Virgin Islands
	 	 	4,754,914	  
		
	 ALLOY VENTURES 2005, L.P.
 Alloy Ventures
 400 Hamilton Avenue, 4th floor

Palo Alto, CA 94301
	 	 	6,255,575	  
		
	 DRAPER FISHER JURVETSON FUND IX, L.P.

Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025
	 	 	3,940,751	  
		
	 DRAPER FISHER JURVETSON PARTNERS IX, LLC

Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025
	 	 	106,789	  
		
	 DRAPER ASSOCIATES, L.P.
 Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	 	 	140,293	  

					
	 INVESTOR
	 	SHARES OF 
PREFERRED
STOCK	 
		
	 WM ORGANIC GROWTH, INC.

WM Organic Growth, Inc.
 1001 Fannin St., Suite 4000
 Houston, TX 77002
	 	 	4,483,209	  
		
	 MITSUBISHI CHEMICAL CORPORATION

General Manager, Mitsubishi Chemical Corporation
 Petrochemicals R&D Division
 14-1 Shiba 4-Chome, Minato-Ku

Tokyo 108-0014, Japan
	 	 	1,630,258	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (DAPER I)

Stanford Management Company
 2770 Sand Hill Road
 Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	 	 	16,703	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (SEVF II)

Stanford Management Company
 2770 Sand Hill Road
 Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	 	 	16,703	  
		
	 THE UCLA FOUNDATION
 10920 Wilshire Blvd., Suite 900
 Los Angeles, CA 90024

Attn: Investment Coordinator
	 	 	16,703	  
		
	 CHRISTOPHER E. GANN
 14770 Caminito Barbuda
 Del Mar, CA 92014
	 	 	266,840	  
		
	TOTAL	 	 	55,532,772	  

 GENOMATICA, INC. 

THIRD AMENDMENT TO 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This
THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this
“Amendment”), amending the Amended and Restated Investor Rights Agreement by and among GENOMATICA, INC., a Delaware corporation (the “Company”), and the investors
listed on Exhibit A thereto (the “Investors”) dated as of December 10, 2010 and amended on January 5, 2011 and February 22, 2011 (as amended, the “Investor Rights Agreement”), is entered
into as of June 20, 2011 by and among the Company and certain of the Investors. Capitalized terms used herein/which are not defined herein shall have the definition ascribed to them in the Investor Rights Agreement. 

RECITALS 
 WHEREAS, the Company and the Investors have previously entered into the Investor Rights Agreement; 

WHEREAS, in connection with an equipment financing line with TriplePoint Capital, LLC (the
“Equipment Financing”), the Company will issue and TriplePoint Capital, LLC will acquire warrants (the “Warrants”) to purchase shares of the Company’s Preferred Stock; 

WHEREAS, pursuant to the Warrants, the Company has agreed to grant TriplePoint Capital, LLC certain
registration rights with respect to the Company’s Preferred Stock issuable upon exercise of the Warrants, and the Company and the Investors desire to amend the Investor Rights Agreement as provided hereunder to provide such registration rights
to TriplePoint Capital, LLC; 
 WHEREAS, Section 5.5 of the Investor Rights Agreement
provides that the Investor Rights Agreement may be amended with the written consent of the Company and (i) the holders of at least a majority of the Registrable Securities then outstanding, (ii) the holders of at least a majority of the
Series B Preferred Stock included in the Registrable Securities then outstanding, (iii) the holders of at least a majority of the Series C Preferred Stock included in the Registrable Securities then outstanding and (iv) the holders of at
least a majority of the Series C-1 Preferred Stock included in the Registrable Securities then outstanding (collectively, the “Required Holders”); and 

WHEREAS, the undersigned constitute the Company and the Required Holders.

 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained herein and in the Investor Rights Agreement, and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Upon
execution of this Amendment, TriplePoint Capital, LLC shall become a party to the Investor Rights Agreement and shall be deemed a “Holder” under the Investor 

 
Rights Agreement, as amended by this Amendment, in each case solely with respect to Sections 2.3, 2.5, 2.7, 2.8, 2.9, 2.11, 2.12, 2.14 and 5 of the Investor Rights Agreement and TriplePoint
Capital, LLC’s signature page to this Amendment shall be deemed to be a counterpart signature page to the Investor Rights Agreement for such purpose. 
 2. Section 1.2(m) of the Investor Rights Agreement. Section 1.2(m) of the Investor Rights Agreement is hereby amended and restated in its entirety as set forth below: 

“(m) “Shares” shall mean the Company’s Series A Stock, Series B Stock, Series C
Stock and Series C-1 Stock held from time to time by the Investors listed on Exhibit A hereto and their permitted assigns, and solely as it relates to Sections 2.3, 2.5, 2.7, 2.8, 2.9, 2.11, 2.12, 2.14 and 5 hereof, the shares of the Company’s
Preferred Stock issued upon exercise of the Warrants.” 
 3. Section 1.2(o) of the Investor Rights
Agreement. A new Section 1.2(o) is hereby added to the Investor Rights Agreement as set forth below: 

“(o) “Warrants” shall mean the warrants issued by the Company to TriplePoint Capital,
LLC to purchase shares of the Company’s Preferred Stock.” 
 4. Section 5.5(a) of the Investor
Rights Agreement. Section 5.5(a) of the Investor Rights Agreement is hereby amended and restated in its entirety as set forth below: 
 “(a) Except as otherwise expressly provided, this Agreement may be amended or modified, and the obligations of the Company and the rights of the Holders under this Agreement may be waived,
only upon the written consent of (i) the Company, (ii) the holders of at least a majority of the Registrable Securities then outstanding, (iii) the holders of at least a majority of the Series B Stock included in the Registrable
Securities then outstanding, (iv) the holders of at least a majority of the Series C Stock included in the Registrable Securities then outstanding and (v) the holders of at least a majority of the Series C-1 Stock included in the
Registrable Securities then outstanding; provided, however, that any amendment or modification to this Agreement or waiver of any term of this Agreement that is not applied to all Investors in the same manner on its face and that
adversely affects the rights of an Investor hereunder in any material respect in a manner different and more adversely than all other Investors shall not be effective as to such Investor without such Investor’s written consent; provided
further, that any amendment, modification or waiver which affects the rights of TriplePoint Capital, LLC under this Agreement differently than the same rights afforded to other Holders shall require the written consent of TriplePoint Capital,
LLC; provided further, for all purposes of this Section it is acknowledged and agreed that the addition of a new party to this Agreement as an “Investor” hereunder, and/or the inclusion of additional classes or series of
stock of the Company as Registrable Securities shall not, in and of itself, be deemed to adversely affect the rights of any Investor.” 

 5. Exhibit A of the Investor Rights Agreement. Exhibit A of the
Investor Rights Agreement shall be amended and restated to read in its entirety as set forth on Exhibit A hereto. 
 6. Effect of Amendment. Except as expressly modified by this Amendment, the Investor Rights Agreement shall remain unmodified and in full force and effect. 

7. Governing Law. This Amendment shall be governed by and construed under the laws of the State of California in
all respects as such laws are applied to agreements among California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof. The parties agree that any action brought by
either party under or in relation to this Amendment, including without limitation to interpret or enforce any provision of this Amendment, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any
state or federal court located in the County of San Diego, California solely for purposes of disputes arising under this Amendment. 
 8. Counterparts. This Amendment may be executed in any number of counterparts and signatures delivered by facsimile, each of which shall be deemed an original, but all of which together shall
constitute one instrument. 
 9. Effectiveness. This Amendment shall be effective as of the effective
date of the Equipment Financing. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	COMPANY:
	
	GENOMATICA, INC.
		
	 By:
	 	 /s/ Christophe Schilling

		 	 Christophe Schilling, Ph.D.

		 	 President and Chief Executive Officer

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
 INVESTORS:

 TPG BIOTECHNOLOGY PARTNERS III, L.P. 
 By: TPG Biotechnology GenPar III, L.P., its general partner 
 By: TPG Biotechnology
GenPar III Advisors, LLC, its general partner 
  

			
	 By:
	 	 /s/ Ronald Cami

		
	 Name:
	 	 Ronald Cami

		
	 Title:
	 	 Vice President

  

			
	 Address:
	 	 c/o TPG Capital, L.P.

		 	 301 Commerce Street

		 	 Suite 3300

		 	 Fort Worth, TX 76102

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
 INVESTORS: 

MDV VIII, L.P. 
 as nominee for 
 MDV VIII, L.P., 

MDV VIII Leaders’ Fund, L.P., and 
 MDV ENF VIII, L.P. 
  

			
	 By:
	 	 Eighth MDV Partners, L.L.C.

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ JOSH GREEN

	 Name:
	 	 JOSH GREEN

	 Title:
	 	 GENERAL PARTNER

  

			
	 Address:
	 	 Mohr, Davidow Ventures
 3000 Sand Hill Road
 Bldg. 3, Suite 290

Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	 INVESTORS:

	
	 ALLOY VENTURES 2005, L.P.

		
	 By:
	 	 Alloy Ventures 2005, LLC

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ CRAIG C. TAYLOR

	 Name:
	 	 CRAIG C. TAYLOR

	 Title:
	 	 Managing Member

  

			
	 Address:
	 	 Alloy Ventures
 400 Hamilton Avenue, 4th floor
 Palo Alto, CA 94301

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	 INVESTORS:

	
	 DRAPER FISHER JURVETSON FUND IX, L.P.

		
	 By:
	 	 /s/ Steve Jurvetson

	 Name:
	 	 Steve Jurvetson

	 Title:
	 	 Managing Director

	
	 DRAPER FISHER JURVETSON PARTNERS IX, LLC

		
	 By:
	 	 /s/ Steve Jurvetson

	 Name:
	 	 Steve Jurvetson

	 Title:
	 	 Managing Member

	
	 DRAPER ASSOCIATES, L.P.

		
	 By:
	 	 /s/ Timothy C. Draper

	 Name:
	 	 Timothy C. Draper

	 Title:
	 	 General Partner

  

			
	 Address:
	 	 Draper Fisher Jurvetson
 2882 Sand Hill Road, Suite 150
 Menlo Park, CA 94025

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	 INVESTORS:

	
	VANTAGEPOINT VENTURE PARTNERS 2006(Q), L.P.
	 By: VantagePoint Venture Associates 2006, L.L.C. Its General Partner

		
	 By:
	 	 /s/ Alan E. Salzman

	 Name:
	 	 Alan E. Salzman

	 Title:
	 	 Managing Member

	
	VANTAGEPOINT CLEANTECH PARTNERS II, L.P.
	 By: VantagePoint CleanTech Associates II, L.P.

	 By: VantagePoint Clean Tech Management, Ltd.

	 Its General Partner

		
	 By:
	 	 /s/ Alan E. Salzman

	 Name:
	 	 Alan E. Salzman

	 Title:
	 	 Chief Executive Officer

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	MITSUBISHI CHEMICAL CORPORATION
		
	 By:
	 	 /s/ Toru Mori

	 Name:
	 	 Toru Mori

	 Title:
	 	 General Manager
 Petrochemicals R&D Division

  

			
	 Address:
	 	 14-1, Shiba 4-Chome, Minato-ku
 Tokyo 108-0014, Japan

 IN WITNESS
WHEREOF, the parties have executed this THIRD AMENDMENT TO AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT as of the date first written above. 
  

			
	INVESTORS:
	
	TRIPLEPOINT CAPITAL, LLC
		
	 By:
	 	 /s/ Sajal Srivastava

		
	 Name:
	 	 Sajal Srivastava

		
	 Title:
	 	 COO

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
  

					
	 INVESTOR
	  	
SHARES OF PREFERRED
STOCK
	 
		
	 TPG BIOTECHNOLOGY PARTNERS III, L.P.

c/o Texas Pacific Group

301 Commerce Street, Suite 3300

Fort Worth, TX 76102
	  	 	12,378,932	  
		
	 ICELAND GENOMIC VENTURES, S.A.

12 rue Gullaume Schuerder

L 2924 Luxemburg
	  	 	3,500,000	  
		
	 MDV VIII, L.P.
 Mohr, Davidow Ventures
 3000 Sand Hill Road

Bldg. 3, Suite 290

Menlo Park, CA 94025
	  	 	10,417,232	  
		
	 VANTAGEPOINT VENTURE PARTNERS 2006 (Q), L.P.

By: VantagePoint Venture Associates 2006, LLC

1001 Bayhill Drive, Suite 300

San Bruno, CA 94066
	  	 	4,075,664	  
		
	 VANTAGEPOINT CLEANTECH PARTNERS II, L.P.

By: VantagePoint CleanTech Associates II, L.P.

By: VantagePoint Clean Tech Management, Ltd.

1001 Bayhill Drive, Suite 300

San Bruno, CA 94066
	  	 	4,075,664	  
		
	 BATIOS HOLDINGS LIMITED

Trident Chambers, P.O. Box 146, Road Town,

Tortola, British Virgin Islands
	  	 	4,754,914	  
		
	 ALLOY VENTURES 2005, L.P.

Alloy Ventures
 400 Hamilton Avenue, 4th floor
 Palo Alto, CA 94301
	  	 	6,255,575	  
		
	 DRAPER FISHER JURVETSON FUND IX, L.P.

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	3,940,751	  
		
	 DRAPER FISHER JURVETSON PARTNERS IX, LLC

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	106,789	  
		
	 DRAPER ASSOCIATES, L.P.

Draper Fisher Jurvetson

2882 Sand Hill Road, Suite 150

Menlo Park, CA 94025
	  	 	140,293	  

					
	 INVESTOR
	  	SHARES OF PREFERRED
STOCK	 
		
	 WM ORGANIC GROWTH, INC.

WM Organic Growth, Inc.

1001 Fannin St., Suite 4000

Houston, TX 77002
	  	 	4,483,209	  
		
	 MITSUBISHI CHEMICAL CORPORATION

General Manager, Mitsubishi Chemical Corporation

Petrochemicals R&D Division

14-1 Shiba 4-Chome, Minato-Ku

Tokyo 108-0014, Japan
	  	 	1,630,258	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (DAPER I)

Stanford Management Company

2770 Sand Hill Road

Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE BOARD OF TRUSTEES OF THE
LELAND STANFORD JUNIOR
 UNIVERSITY (SEVF II)

Stanford Management Company

2770 Sand Hill Road

Menlo Park, CA 94025

Attn: Jin Gu / Martina Poquet
	  	 	16,703	  
		
	 THE UCLA FOUNDATION

10920 Wilshire Blvd., Suite 900

Los Angeles, CA 90024

Attn: Investment Coordinator
	  	 	16,703	  
		
	 CHRISTOPHER E. GANN

14770 Caminito Barbuda

Del Mar, CA 92014
	  	 	266,840	  
		
	 TRIPLEPOINT CAPITAL, LLC

2755 Sand Hill Road

Menlo Park, CA 94025
	  	 	To be determined	  
		
	 TOTAL
	  	 	56,076,190Plain English Equipment Loan and Security Agreement

 Exhibit 10.23 
 

 
 PLAIN ENGLISH EQUIPMENT LOAN
AND SECURITY AGREEMENT 
 This is a PLAIN ENGLISH EQUIPMENT LOAN AND
SECURITY AGREEMENT dated as of June 20, 2011 by and between GENOMATICA, INC., a Delaware corporation, as borrower, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company, as lender. 

The words “We”, “Us”, and “Our” refer to TRIPLEPOINT CAPITAL LLC. The words “You” and
“Your” refer to GENOMATICA, INC., not to any individual. The words “the Parties” refers to both TRIPLEPOINT CAPITAL LLC and GENOMATICA, INC. This Plain English Equipment Loan and Security Agreement may be referred to as the
“Agreement”. 
 The Parties agree to the following mutual agreements and conditions listed below: 

EQUIPMENT LOAN FACILITY INFORMATION 
  

							
	 Facility Number
	  	 Commitment Amount

		
	 Part 1: 0693-LO-01H/ 0693-LO-01S

 
 Part 2: 0693-LO-02HZ 0693-LO-02S
	  	 Part 1: $4,000,000 (of which up to $600,000 (15%) may

be used for software and Soft Costs)
  

Part 2: $4,000,000 Upon Request and Additional
 Approval and mutually agreed upon terms.

				
	 Minimum Advance

Amount
	 	 Availability Period
	  	 Loan Term
	  	 Facility Fee

				
	None	 	 Part 1: 6/20/11 through
 12/31/2011
  
 Part 2: TBD
	  	 Part 1:42 Months, subject to
 adjustment as set forth in
 Section 11.

 
 Part 2: TBD
	  	 Part 1: $30,000
  

Part 2: TBD

  

					
	 Interest Rate
	  	 End Of Term Payment
	  	 Right to Invest

	 Part 1: Prime Rate plus 4.75%

 
 Part 2: TBD

 
 (Interest rate to be fixed at time of each Advance;
Prime Rate as published in the Wall Street Journal the day before any Advance is funded however, in no event shall the Prime Rate be less than 3.25%)
	  	 Part 1: 6% of each Advance for
 equipment not consisting of software,
 10% for each Advance used for

software.
  

Part 2: TBD
	  	 You grant Us the right to invest up to

$250,000 in Your next round of equity
 financing per Section 20 A.

 OUR CONTACT INFORMATION 

 

					
	 Name
	  	 Address For Notices
	  	 Contact Person

			
	TriplePoint Capital LLC	  	 2755 Sand Hill Rd., Ste. 150
 Menlo Park, CA 94025
 Tel: (650) 854-2090

Fax: (650) 854-1850
	  	 Sajal Srivastava, COO
 Tel: (650) 233-2102
 Fax: (650) 854-2094

email: legal@triplepointcapital.com

 YOUR CONTACT INFORMATION 

					
	 Customer Name
	  	 Address For Notices/Billing
	  	 Contact Person

			
	Genomatica, Inc.	  	 10520 Wateridge Circle
 San Diego, CA 92121
 858-363-8571

 
 (Unless Noted Differently On Promissory Notes, the
Equipment Location is the Same as Above)
	  	 Tom McDonald, Sr. Dir. Finance
 Tel: 858-362-8563
 Fax: 858-824-1772

email: tmcdonald@genomatica.com

 Capitalized terms defined in the table on Page 1 and 2 of this Agreement shall have the meanings given to
those terms in such table, and other capitalized terms not otherwise defined in the body of this Agreement are defined in Section 22. Any accounting term not specifically defined herein shall be construed in accordance with GAAP, and all
calculations shall be made in accordance with GAAP. The term “financial statements” shall include the accompanying notes and schedules. 
  

 

	1.	 WHAT THE PARTIES AGREE TO FINANCE 

 
 Provided that the conditions in
Sections 6 and 7 and elsewhere in this Agreement are met, We will lend to You the Commitment Amount as reflected on Page 1 of this Agreement and You agree to use such proceeds only to finance Equipment, as defined below. We will lend to You advances
(each an “Advance”) in minimum amounts as set forth on Page 1 of this Agreement up to a maximum of the Commitment Amount as provided on Page 1. Our obligation to fund Advances under this Agreement will end on the last day of the
Availability Period noted on Page 1. 
 “Equipment” will consist of all present and future existing standard,
third party off-the-shelf resalable equipment, as such term is defined in the UCC, consisting of personal computers, laptops, workstations, routers, phone systems, office equipment, electronic test equipment, manufacturing equipment, production
equipment, medical device equipment, healthcare testing equipment, biotechnology equipment, office furniture and other equipment that We approve in writing. Distilled skids and fermentation tanks are also considered Equipment for purposes of this
Agreement. Equipment WILL NOT (unless otherwise noted in this Agreement) include rolling stock, custom or specialized equipment, installation costs, delivery costs, freight, leasehold improvements, special tooling and molds, software, handheld
items, taxes and other fungible items. 
 Notwithstanding anything else, Equipment for purposes of the Part 1 Commitment Amount
shall include software and Soft Costs (as defined) related to the Equipment. 
 “Soft Costs” shall include
shipping/handling, warranties and installation costs associated with the Equipment. 
  

 

	2.	 YOU WILL ENTER INTO MULTIPLE PROMISSORY NOTES 

 
 The Plain English Promissory Note
in the form of Exhibit A (the “Promissory Note”) is the document the Parties will enter into each time an Advance is to be funded. The Promissory Note will contain the specific financial terms of the Advance (e.g. amount funded,
interest rate, maturity date, advance date, payment due dates etc.) and all of the terms and conditions of this Agreement are incorporated in and made a part of each Promissory Note. There may be multiple Promissory Notes associated with this
Agreement. 
  
  

	3.	 YOUR LOAN FACILITY COMMITMENT AMOUNT MAY BE DIVIDED INTO PARTS 

 
 The Commitment Amount and/or its
corresponding parts (if any) will be noted on Page 1 of this Agreement (“Parts”). For purposes of this Agreement, references to the Commitment Amount shall mean the Part or Parts which are available and in effect. Certain terms or
conditions associated with the availability of such Part are listed on Page 1 of this Agreement. As to any Part that is available “Upon Request and Additional Approval”, You are required to make a request to utilize that additional
Part in writing to Us (the “Commitment Increase Request Notice”), prior to Your submission of a corresponding Advance Request. After Our receipt of the Commitment Increase Request Notice, We will review the information available to
Us and conduct any legal and business due diligence deemed necessary by Us in connection with Our attempt to obtain Our requisite credit approvals. Our agreement to consider providing the additional Part is not, and is not to be construed as, a
commitment, offer, or agreement to provide such additional Part. 

  
 2 

  

	4.	 ORDERING EQUIPMENT 

 
 You may order Equipment from any
vendor, manufacturer or third party of Your choice. You will select all of Your Equipment and will not rely on Us at all when selecting Your Equipment. We may offer services to assist You in ordering Equipment. You are under no obligation to use
these services. Not all of the Equipment that You order may be eligible for placement under this Agreement – only Equipment which meets the terms and conditions of this Agreement may be placed on this Agreement, as determined in Our sole
discretion. 
 You are responsible for all ordering, delivery, and transportation expenses as well as in-transit insurance to
Your premises and installation and set-up costs of the Equipment. These expenses are not covered under this Agreement, except to the extent of any Soft Costs permitted under this Agreement. 

 
  

	5.	 PAYING FOR THE EQUIPMENT 

 
 You must fully pay for the
Equipment and request Advances from Us in order for Us to reimburse You. In addition to the requirements of Section 6 and 7 set forth below, Our obligation to make any Advance is contingent upon all of the following conditions being met to Our
satisfaction: 
  

	•	 	 The Equipment meets the definition of Equipment. 

  

	•	 	 You have timely submitted the invoices for the Equipment, proof of payment and the Advance Request to Us as outlined below in Section 6.

  

	•	 	 The amount of the Advance Request plus the aggregate amount of all other Advances that We have already made to You does not exceed the Commitment
Amount currently available. 

  

	•	 	 The amount of the Advance Request does not exceed one hundred percent (100%) of the invoice amount of the Equipment and Soft Costs, as
permitted, that are eligible to be financed under this Agreement, excluding tenant improvements, taxes, shipping, warranty charges, freight discounts, installation expenses or other costs or expenses for which You are responsible.

  

	•	 	 You shall have purchased the Equipment that is the subject of each Advance within the period outlined in Section 6.

  
  

	6.	 HOW YOU WILL REQUEST ADVANCES 

 
 In addition to the requirements of
Section 7 set forth below, You agree to deliver the information and documents listed below (collectively, the “Designated Information”) as a condition to having Us extend an Advance to You: 

 

	•	 	 You will submit to Us (by facsimile, mail or electronic mail) a completed Advance Request in the form attached as Exhibit B signed by Your
Chief Executive Officer, President or Chief Financial Officer. 

  

	•	 	 Such Advance Request must be submitted and received by Us no later than 5:00 p.m. PT ten (10) Business Days prior to the last day of the
applicable Availability Period. Any Advance Request submitted after 5:00 p.m. PT will be considered received the following Business Day. 

  

	•	 	 Each Advance Request will state a requested funding date that is at least ten (10) Business Days after the date such Advance Request is
submitted to Us. 

  

	•	 	 In addition to the Advance Request, You will submit the invoices for the Equipment and proof of payment and any further proof that We may reasonably
require to indicate You have clear title and ownership of the Equipment, such proof to be reasonably satisfactory to Us. 

  

	•	 	 You will submit serial numbers, inventory numbers and any other identifying marks We request of the Equipment to Us (We may provide You with an
electronic spreadsheet for You to complete this information). 

 After We check and confirm the information
You provide in the Advance Request We will prepare and provide to You a Promissory Note and an amortization schedule for Your signature. Upon receipt of the Promissory Note signed by Your authorized officer and confirmation that all of the
conditions have been met, We will then make an Advance to You based on the following: 

  
 3 

	•	 	 For Equipment purchased after the Closing Date, and for which the Designated Information has been submitted to Us within thirty (30) days after
the invoice date: 100% of original net Equipment cost. 

  

	•	 	 For Equipment purchased one hundred and twenty (120) days or less before the Closing Date, and for which the Designated Information has been
submitted to Us within the first thirty (30) days after the Closing Date: 100% of original net Equipment cost. 

 All the terms, conditions, and covenants of this Agreement shall apply to all Advances whether or not each Advance is evidenced by a Promissory Note. You agree that We may rely on, and shall be fully
protected in relying upon, any notice or Advance Request given by any person We reasonably believe to be Your authorized representative without the necessity of Our conducting an independent investigation, including Your contact person listed on
Page 1. 
  
  

	7.	 CONDITIONS FOR US TO MAKE LOANS TO YOU 

 
 Our obligation to fund any Advance
that You request under this Agreement is subject to satisfaction of each of the conditions set forth in Sections 6 and 19 and each of the following conditions: 
  

	 	•	 	 The representations and warranties in this Agreement and in the Warrant Agreement shall be true, complete and correct in all material respects on
and as of the date(s) We fund such Advance with the same effect as though they were made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they shall remain true,
complete and correct in all material respects as of such date; provided, however, that such materiality qualifiers shall not be applicable to any representations and warranties that already are qualified or modified by materiality in
the text thereof. Each Advance Request will constitute Your representation and warranty on the relevant Advance date as to the matters provided in Sections 13 and 14 and as to the matters set forth in the Advance Request.

  

	 	•	 	 You shall be in compliance with all the terms and provisions set forth in this Agreement, each Promissory Note and each other Loan Document, and at
the time of and immediately after such Advance: (a) no Default or Event of Default (as defined in Section 16) shall have occurred and be continuing, and (b) no fact or conditions shall exist that would (or would with the passage of
time, the giving of notice, or both) constitute an Event of Default under this Agreement or any other Loan Document. 

  

	 	•	 	 You are not in default under any other agreement with Us or any other lessor or lender, the result of which would allow the lessor, lender or any
secured party to demand immediate payment: 

  

	 	•	 	 You shall provide Us with all appropriate assignments, notices and other agreements that are necessary or desirable to perfect or maintain Our first
priority Lien in all of the Collateral. 

  

	 	•	 	 You shall have paid to Us the Facility Fee relating to such Advance. 

 

	 	•	 	 No event or circumstance shall exist or have occurred that has had or could reasonably be expected to have a Material Adverse Effect.

  

	 	•	 	 You shall submit Your Advance Request to Us not later that the last day of the Availability Period. 

 

	 	•	 	 You shall have delivered to Us the Warrant Agreement. 

 

	 	•	 	 You shall submit to Us any other documents and other information that We may reasonably request. 

 
  

	8.	 YOU MAY PREPAY YOUR PROMISSORY NOTES 

 
 You may at any time prepay any
Promissory Notes in full, without any premium or penalty, by paying the remaining outstanding principal amount and all accrued interest calculated as if the date of such prepayment occurred on the next scheduled monthly payment date per the
respective Promissory Note and the End of Term Payment, if any. 

  
 4 

  

	9.	 THE MAXIMUM RATE OF INTEREST 

 
 Maximum Rate of
Interest. It is not Our intent to receive interest at a rate greater than the maximum rate permissible by law, which We shall call the “maximum rate”. If a court determines You have actually paid Us interest based on a rate that
exceeds the maximum rate, then We shall apply the excess as follows: first, to the payment of the outstanding principal amount of the Secured Obligations; second, after all principal is repaid, to the payment of Our accrued interest
and any other principal, interest, fees, costs or other amounts owed by You to Us in respect of the Secured Obligations; and third, after all amounts owed by You to Us are repaid, the excess (if any) shall be refunded to You. 

Default Interest. In the event that You do not pay any interest when due, delinquent interest shall be added to principal
and shall bear interest on interest, compounded at the rate set forth in Page 1. Upon and during an Event of Default, all principal, interest or other amounts owed by You to Us shall bear interest at a rate per annum equal to the rate set
forth in Page 1 plus five percent (5%) per annum (the “Default Rate”). 
  

 

	10.	 YOU OWN THE EQUIPMENT AND GRANT USA SECURITY INTEREST 

 
 You grant to Us a first priority,
continuing security interest in and Lien upon all of Your right, title and interest in all Equipment financed under this Agreement now existing or acquired in the future, wherever it may be located, and all proceeds of such Equipment and all
additions, upgrades, and accessions to, substitutions and replacements for such Equipment, together with all attachments, components, parts, and accessories installed thereon or affixed thereto, and rents, profits and products thereof (collectively,
the “Collateral”). 
  
  

	11.	 HOW AND WHAT WILL YOU PAY US 

 
  

	 	•	 	 Payments. The principal balance of each Promissory Note shall accrue interest at the percentage per year as indicated on Page 1 of this
Agreement, and shall be computed daily on the basis of a year consisting of 360 days for the actual number of days occurring in the period for which such interest is payable, and interest shall accrue from the date on which the Advance evidenced by
such Promissory Note is funded to You. Each Promissory Note shall be due in forty-two (42) equal monthly installments of principal and interest, payable on the last day of each month through the last payment date (unless that date falls on a
weekend or national holiday in which event such payment shall be due on the previous business day). The first payment date for each Advance will be the last day of the month in which the Advance was funded. All payments shall be free and clear of
any taxes, withholdings, duties, impositions or other charges, to the end that We will receive the entire amount of any Secured Obligations payable under this Agreement, regardless of the source of payment. 

Any amounts that You repay on the Advances may not be re-borrowed. 

 

	 	•	 	 Adjustment of Payment Terms. If on or before March 31, 2013, (i) You have issued and sold additional shares of Your capital stock
since the Closing Date for aggregate gross cash proceeds of at least $40,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness), subject to confirmation satisfactory to Us, (the “Milestone Equity Event”),
(ii) You are current on all payments due and payable in respect of all Secured Obligations, (iii) no Default or Event of Default (as defined in Section 16) has occurred and is continuing, and (iv) You have delivered to Us written
notice no later than ten (10) days after the closing of the Milestone Equity then You may elect (by delivery to Us of a written notice of such election), effective as of the last day of the month during which in which You have provided Us the
notice of election, to extend the monthly installments of principal and interest under each Promissory Note by an additional three months for total monthly installments of forty-five (45) months. In the event You elect this option, amended and
restated Promissory Note(s) shall be issued by You in favor of Us to evidence the adjustment payment term. 

  

	 	•	 	 Miscellaneous. Payments are due electronically by automatic debit through Automated Clearing House (ACH) payment on or before the last day of
each month. You agree to fill out and execute the electronic funds transfer/automatic debit Authorization form that We provide. If We do not receive any payments from You within two (2) business days after they are due (through no fault of Our
own), You will pay a late charge on the overdue amount. The late charge will be equal to five percent (5%) of the amount due for each month not paid when due and until such time as payment is received. All payments shall be free and clear of
any taxes, withholdings, duties, 

  
 5 

	 	 
impositions or other charges, to the end that We will receive the entire amount of any Secured Obligations payable under this Agreement, regardless of the source of payment. Any interest not paid
when due shall be compounded by becoming a part of the Secured Obligations, and such interest shall then accrue interest at the rate then applicable under this Agreement and the applicable Promissory Note. 

 
  

	12.	 INSURANCE, RISK OF LOSS, AND DAMAGE TO THE EQUIPMENT 

 
 So long as there are any Secured
Obligations outstanding (other than inchoate indemnity obligations), You agree to the following: 
  

	•	 	 You relieve Us of responsibility for all risks of physical damage to or loss or destruction of the Collateral (except to the extent of Our gross
negligence or willful misconduct). 

  

	•	 	 You shall carry and maintain insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, including the
perils of fire and windstorm in an amount not less than either (i) the replacement value of the Collateral or (ii) the greater of the fair market value of the Collateral or the lump sum of the unpaid balance of the remaining monthly
payments under this Agreement plus the percentage used to calculate the End of Term Payment, if any, of the Collateral’s original purchase price. You shall carry and maintain casualty insurance for each item of Collateral from an insurance
provider who is acceptable to Us. All such insurance shall be in form, with companies, and in amounts reasonably acceptable to Us (the insurance in effect as of the Closing Date is acceptable to Us). 

 

	•	 	 You shall submit to Us certificates of insurance, which reflect Your compliance with Your insurance obligations under this Agreement. The
certificates of insurance shall state that (i) We are an additional insured and a loss payee for all risk property damage insurance; (ii) the coverage evidenced is primary and non-contributory to any insurance obtained by Us; and
(iii) a waiver of subrogation in favor of Us has been agreed to. The certificates shall further provide for a minimum of thirty (30) days advance written notice to Us of cancellation or any other change adverse to Our interests. Any
failure by Us to scrutinize such insurance certificates is not a waiver of any of Our rights, all of which are reserved. 

  

	•	 	 You shall provide Us with certificates or other evidence of insurance reasonably acceptable to Us upon the occurrence of Our funding each Promissory
Note. In the event that You do not provide Us with proof of insurance within thirty (30) days of the Advance Date of a Promissory Note, We will obtain such insurance on Your behalf and charge You for such insurance, plus a twenty percent
(20%) administrative surcharge. 

  

	•	 	 If the Collateral is ever damaged, You will promptly repair it, unless such Collateral is either lost or totally destroyed. Within fifteen
(15) days of the loss or total destruction of the Collateral, You must provide written notice of that loss to Us. You will have the option to either: (a) replace the item of Collateral with the same or better model, type, manufacturer and
configuration, or (b) prepay the applicable portion of the Advances by paying the outstanding principal amount for such Collateral, accrued interest and the End of Term Payment related to that portion paid 

 

	•	 	 If any insurance proceeds are paid as a result of any such loss or damage to the Collateral, You agree that such insurance proceeds shall be paid to
Us and We will apply it towards Your payment obligations under this Agreement, except to the extent such proceeds are used by You to repair the Collateral subject to loss. 

 

	•	 	 You agree to carry bodily injury and property damage liability insurance during the term of any Promissory Note and against risks customarily
insured against. Your insurance certificate shall state that We are an additional insured for commercial general liability. 

  

 

	13.	 REPRESENTATIONS AND WARRANTIES FROM YOU 

 
 You represent and warrant to Us that: 

 

	•	 	 Collateral Title. You own all right, title and interest in and to the Collateral, free of all Liens whatsoever, except for Permitted Liens.

  

	•	 	 Granting of Lien. You have the full power and authority to, and do grant and convey to Us, a Lien on the Collateral as security for the
Secured Obligations free of all Liens other than Permitted Liens, and shall execute such notices, 

  
 6 

	 	 
assignments, and other agreements, in connection herewith, as We may reasonably request to perfect and obtain the priority of Our Lien on the Collateral. Except for Permitted Liens, the
Collateral is not subject to any Liens. 

  

	•	 	 Due Organization. You are a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware with
corporate organization number 4441521 and are duly qualified as a foreign corporation in all jurisdictions in which the nature of Your business or location of Your properties requires such qualifications and where the failure to be qualified would
result in an event which individually or together with any other event, could reasonably be expected to have a Material Adverse Effect. 

  

	•	 	 Authorization, Validity and Enforceability. Your execution, delivery and performance of the Promissory Notes, this Agreement, all financing
statements, all other Loan Documents (i) have been duly authorized by all necessary corporate action, and (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than the Liens created by this Agreement
and the other related Loan Documents. The person or people executing this Agreement and other Loan Documents are duly authorized to do so, and the Loan Documents and each term and provision thereof are Your legal, valid and binding obligations,
enforceable in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization or other similar laws generally affecting the enforcement of the rights of creditors and equitable principles (regardless of whether
enforcement is sought in equity or at law). 

  

	•	 	 Litigation. There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to Your
knowledge, threatened against You or any of Your business or property (i) which involve any Loan Document or Excluded Agreement or (ii) as to which there is a reasonable possibility of an adverse determination and which, if adversely
determined, could, individually or in the aggregate result in an event which individually or together with any other event, would have a Material Adverse Effect. 

 

	•	 	 Compliance with Applicable Laws. You are not in violation of any law, rule or regulation or in default with respect to any judgment, writ,
injunction or decree of any governmental authority, where such violation or default could reasonably be expected to result in a Material Adverse Effect. 

 

	•	 	 Conflict. Neither this Agreement nor any other Loan Document (a) violates any provisions of Your articles or certificate of
incorporation, bylaws or any law, regulation, order, injunction, judgment, decree or writ to which You are subject or (b) conflicts with or results in the breach or termination of, constitutes a default under or accelerates or permits the
acceleration of any performance required by, any material lease, agreement or other contract to which You are a party or by which You or any of Your property is bound. 

 

	•	 	 Further Consent. The execution, delivery and performance of this Agreement and the other Loan Documents do not require the consent or
approval of any other person, including any regulatory authority, or governmental body of the United States or any State or any political subdivision or the United States or any state. 

 

	•	 	 Material Adverse Effect. From April 1, 2011 through the Closing Date, no event that has had or could reasonably be expected to have a
Material Adverse Effect has occurred or is continuing. 

  

	•	 	 Other Defaults. You are not in default in any manner under any provision of any indenture or other agreement or instrument evidencing
Indebtedness in excess of $50,000, or any other material agreement or instrument to which You are a party or by which You or any of Your properties or assets are or may be bound, in each case where such default could result in an event which,
individually or together with any other event, could reasonably be expected to have a Material Adverse Effect. 

  

	•	 	 Information Correct. No information, report, financial statement, exhibit or schedule furnished by or on behalf of You to Us in connection
with the negotiation of any Loan Document contains any material misstatement of fact or omits to state any material fact necessary to make the statements, in the light of circumstances under which they were, are or will be made, not misleading; it
being understood by Us that projections and forecasts provided by You that have been prepared in good faith and that are based on reasonable assumptions, are not to be viewed as facts, and that actual results during the periods covered by such
projections and forecasts may differ from the projected and forecasted results. 

  

	•	 	 Filing of Taxes. Subject to Section 14, You have (a) filed all required federal, state and local tax returns (or filed appropriate
extensions for the filing of such returns) except to the extent such failure to file has not resulted in the creation of a Lien and (b) fully paid or You have reserved for and are contesting in good faith all taxes or installments

  
 7 

	 	 
(including any interest or penalties) that are due and payable. You have fully paid or reserved for and are contesting in good faith all tax assessments that You have received for the 3 years
preceding the Closing Date. 

  

	•	 	 ERISA Compliance. You have met the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No
event has occurred resulting from Your failure to comply with ERISA that is reasonably likely to result in Your incurring any liability that could reasonably be expected to have a Material Adverse Effect. 

 

	•	 	 Hazardous Waste. None of Your properties or assets has ever been used by You or, to Your knowledge, by previous owners or operators, in the
disposal of, or to produce, store, handle, treat, release, or transport, any hazardous waste or hazardous substance other than in accordance with applicable law; to Your knowledge, none of Your properties or assets has ever been designated or
identified in any manner pursuant to any environmental protection statute as a hazardous waste or hazardous substance disposal site, or a candidate for closure pursuant to any environmental protection statute; no Lien arising under any environmental
protection statute has attached to any revenues or to any real or personal property owned by You; and You have not received a summons, citation, notice, or directive from the Environmental Protection Agency or any other federal, state or other
governmental agency concerning any action or omission by You resulting in the releasing, or otherwise disposing of hazardous waste or hazardous substances into the environment. 

 

	•	 	 Your Information. Your present name, former names (if any) used in the past 5 years, locations, and other information are correctly stated on
the attached Exhibit C. 

  

	•	 	 Operation of Business. You own, possess, have access to, or can become licensed on reasonable terms under all patents, patent applications,
trademarks, trade names, inventions, franchises, licenses, permits, computer software and copyrights necessary for the operation of Your business as now conducted, with no known infringement of, or conflict with, the rights of others. You have taken
reasonable measures to avoid liability from infringement by third parties using your facilities; in particular You have complied with the requirements of the Digital Millennium Copyright Act for notice and takedown. 

 
  

	14.	 YOUR COVENANTS TO US 

 
  

	•	 	 Legal Existence and Qualification. You will maintain Your, and each of Your Subsidiaries’, legal existence and good standing in Your and
their respective jurisdictions of formation or organization, and maintain qualifications to do business in all jurisdictions in which the nature of Your business or location of Your properties require such qualifications and where the failure to be
qualified would result in an event which, individually or together with any other event, would have a Material Adverse Effect. 

  

	•	 	 Compliance with Laws. You will comply with all laws (including, without limitation, environmental laws) rules, regulations applicable to, and
all orders and directives of any governmental or regulatory authority having jurisdiction over, You or Your business, and with all material agreements to which You are a party, except where the failure to so comply would not have a Material Adverse
Effect. You shall not become an “investment company” or controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of Your important
activities, the business of extending credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any loan for such purpose. You shall not fail to meet the minimum funding requirements of ERISA, permit a reportable event or
prohibited transaction, as defined in ERISA, to occur, fail to comply with the Federal Fair Labor Standards Act. 

  

	•	 	 Mergers. You will not liquidate, dissolve or enter into or consummate any Merger Event without Our prior written consent or payment in full
of all Secured Obligations in connection with the consummation of such Merger Event. 

  

	•	 	 Additional Documents and Assurances. You will from time to time execute, deliver and file, alone or with Us, any security agreements, or
other documents to perfect or give first priority to Our Lien on the Collateral. You will from time to time obtain any instruments or documents as We may reasonably request, and take all further action that may be reasonably necessary or desirable,
or that We may reasonably request, to carry out the provisions and purposes of this Agreement or any other Loan Document or to confirm, perfect, preserve and protect the Liens granted to Us in this Agreement. In addition, You authorize Us to file at
any time financing statements, continuation statements, and 

  
 8 

	 	 
amendments thereto that (i) either specifically describe the Collateral or describe the Collateral as all of Your assets of the kind pledged hereunder, and (ii) contain any other
information required by the UCC for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment, including whether You are an organization, the type of organization and any organizational
identification number issued to You, if applicable. You hereby appoint Us as Your lawful attorney-in-fact to sign Your name on any documents necessary to perfect or continue the perfection of any Lien regardless of whether an Event of Default has
occurred until all Secured Obligations (other than inchoate indemnity obligations) have been satisfied in full and We are under no further obligation to make Advances. Our foregoing appointment as Your attorney in fact, and all of Our rights and
powers, coupled with an interest, are irrevocable until all Secured Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Our obligation to provide Advances terminates. 

 

	•	 	 Protection of Our Lien. You will protect and defend Your title to the Collateral and Our Lien on the Collateral. You shall at all times keep
the Collateral free and clear from any legal process or Liens whatsoever (except for Permitted Liens) and shall give Us immediate written notice of any legal process affecting the Collateral, or any Liens on the Collateral (other than Permitted
Liens). 

  

	•	 	 Dispositions, Liens and Encumbrances. You will not transfer, sell, assign, grant a security interest in, hypothecate, permit or suffer to
exist any Lien, or otherwise transfer any interest in or encumber any portion of the Collateral, either voluntarily or involuntarily, without Our prior written consent, other than Permitted Liens, In addition, You will not enter into any agreement
with any other person that restricts Your ability to transfer, sell, assign, grant a security interest in, hypothecate, permit or suffer to exist any Lien, or otherwise transfer any interest in or encumber any portion of the Collateral.

  

	•	 	 Financial Statements. You will provide monthly and yearly financial statements in accordance with Section 19.

  

	•	 	 Dividends and Distributions. Prior to Your initial public offering, You will not, without Our prior written consent, declare or pay any cash
dividend or make a distribution on, or repurchase or redeem, any class of stock, in excess of an aggregate of $100,000 in any calendar year, other than pursuant to employee repurchase plans upon an employee’s death or termination of employment
and other than dividends and distributions paid solely in Your capital stock. 

  

	•	 	 Audits and Inspections. Upon Our request, You will, during normal business hours, make the Collateral, and books and records concerning the
Collateral (including software used in Your business) available to Us for inspection at the place where it is located and shall make Your log and maintenance records pertaining to the Collateral available to Us for inspection. You will take all
action necessary to correctly and completely maintain such books, records, logs, and maintenance records. 

  

	•	 	 Inventory Tags. You authorize Us to insert serial numbers or other inventory data on the Equipment. We will provide You with inventory tags
to indicate Our security interest in the Equipment. You will mark the Equipment with these inventory tags within 30 days of receipt of the inventory tags. You will keep all Equipment free from any other marking or tags that might be interpreted as a
claim of ownership. 

  

	•	 	 Taxes. You must pay when due all taxes fees or other charges of any nature whatsoever (together with any related interest or penalties)
imposed or assessed against You, Us (as it relates to the Collateral or the financing provided by Us to You) or the Collateral or upon Your ownership, possession, use, operation or disposition thereof or upon Your rents, receipts or earnings arising
therefrom (excluding taxes imposed on Us based on Our net income or franchise taxes). You shall file on or before the due date all federal, state and local tax returns including personal property tax returns in respect to the Collateral.
Notwithstanding the foregoing, You may contest, in good faith and by appropriate proceedings, taxes for which You maintain adequate reserves in accordance with GAAP. 

 

	•	 	 Intellectual Property. You will: protect, defend and maintain the validity and enforceability of Your Intellectual Property to the extent
material to Your business. 

  

	•	 	 Collateral Locations; Name Changes. You will not relocate Your chief executive office or Your principal place of business or any item of the
Collateral (other than mobile equipment and temporary relocations of Collateral with an original cost less than $25,000) unless: (i) You have given Us no less than thirty (30) days prior written notice, (ii) such relocation shall be
within the continental United States, and (iii) such relocation does not adversely affect the 

  
 9 

	 	 
perfection or priority of Our security interest in any of the Collateral. In addition, You will obtain and maintain such acknowledgments, consents, waivers and agreements from: (i) the
owner, Lien holder, mortgagee and landlord with respect to any real property on which Collateral is located and (ii) from any Person in possession of Collateral, as We may reasonably require, all in form and substance reasonably satisfactory to
Us. Without limiting the foregoing, where the Collateral is covered by a negotiable Document (such as a warehouse receipt), You shall deliver to Us possession of such Document. 

 

	•	 	 Line of Business. You shall not engage in any business other than the businesses currently engaged in by You or reasonably related thereto
(or if not reasonably related, Your current investors continue to fund, or arrange for the funding of, You in the amounts and timeframe reasonably necessary to enable You to satisfy the Secured Obligations as they become due and payable).

  

	•	 	 Change of Jurisdiction. You will not change Your state of organization unless You have given Us no less than fifteen (15) days prior
written notice prior to changing Your state of organization. 

  

	•	 	 Care, Use, and Maintenance of the Equipment. You will install and maintain the Equipment in good working condition (taking into consideration
ordinary wear and tear) and make all necessary and proper repairs, renewals and replacements in accordance with prudent industry standards. You will protect the Equipment from damage and any other kind of loss while You have the Equipment or while
it is being delivered to You. Even if the Equipment is damaged or lost, You will continue to pay the monthly payments. You will only use the Equipment in the Continental United States and for business purposes and in compliance with all applicable
laws. The Equipment will not be used by an entity exempt from federal income tax. You will not make any material alterations to the Equipment without Our prior written consent (which We will not unreasonably withhold) nor will You permanently attach
the Equipment to any real estate. 

  
  

	15.	 YOU AGREE TO INDEMNIFY AND PROTECT US 

 
 You agree to indemnify and hold Us,
Our officers, directors, employees, agents, attorneys, representatives and shareholders (collectively, the “Indemnified Persons”) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such
claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort) (collectively, “Claims”), including reasonable attorneys’ fees and disbursements and other costs of investigation or
defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Us or any such Person as a result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents
or the administration of such credit, or in connection with or arising out of the transactions contemplated or as the result of any actions or failures to act in connection with, or arising out of the disposition or utilization of the Collateral,
including but not limited to the selection, delivery, return, installation, possession, ownership, use, operation, control, or maintenance of the Collateral, but excluding in all cases Claims to the extent resulting solely from any Indemnified
Person’s gross negligence or willful misconduct. We will notify You within 20 days of any Claims and You will be entitled to control the defense and any settlement of such Claims without Our consent. We agree not to settle any Claim without
Your prior written consent, and to cooperate in providing You with any support and/or information reasonably requested by You to assist in defending any such Claims. 
  

 

	16.	 WHAT IS AN EVENT OF DEFAULT 

 
 The occurrence of any one or more
of the following events shall constitute an “Event of Default” under this Agreement: 
  

	•	 	 Payment. You do not pay any principal, interest, fees, costs or other Secured Obligations under this Agreement, the Promissory Notes or any
of the other related Loan Documents on the due date; or 

  

	•	 	 Covenant. You fail to perform any covenant or Secured Obligations under this Agreement, the Promissory Notes or any of the other related Loan
Documents, and You fail to cure such breach (to the extent that such breach is capable of being cured) within ten (10) days after the earlier of (i) We give You written notice or (ii) Your actual knowledge of such default; or

  

	•	 	 Misrepresentations. You or any Person acting for You makes any representation, warranty, or other statement now or later in this Agreement,
any other Loan Document, or any Excluded Agreement or in any writing delivered to Us or to 

  
 10 

	 	 
induce Us to enter this Agreement, any other Loan Document, or any Excluded Agreement, and such representation, warranty, or other statement is incorrect in any material respect when made,
provided, however, that such materiality qualifier shall not be applicable to any representation, warranty or statement that already is qualified or modified by materiality in the text thereof; or 

 

	•	 	 Bankruptcy; Attachment; Other. 

  

	 	•	 	 You (i) assign Your assets for the benefit of Your creditors, (ii) become insolvent or become unable to pay Your debts as they become due,
or You become unable to pay or perform Your obligations under the Loan Documents or Excluded Agreements, (iii) file a voluntary petition in bankruptcy, (iv) file any petition, answer, or document seeking for Yourself any reorganization,
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances, (v) seek or consent to or acquiesce in the appointment of any trustee,
receiver, or liquidator of Yours or of all or any substantial part of Your assets or property, (vi) commence efforts to wind down Your business activities for the goal of shutting down Your operations, or (vii) You or Your directors or
majority shareholders shall take any action initiating any of the foregoing actions described in this paragraph; or 

  

	 	•	 	 Either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against You seeking reorganization,
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation , without such action being dismissed or all orders or proceedings thereunder affecting Your operations or the
business being stayed; or (ii) a stay of any such order or proceeding shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) You shall file any answer admitting or not contesting the material
allegations of a petition filed against You in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or 

 

	 	•	 	 Forty-five (45) days shall have expired after the appointment, without Your consent or acquiescence, of any trustee, receiver or liquidator of
Yours or of all or any substantial part of Your properties without such appointment being vacated; or 

  

	•	 	 Agreements with Us. The occurrence of any default under any other Loan Document, any Excluded Agreement, or any other agreement between You
and/or any of Your Subsidiaries and Us (other than any default embodied in or covered by any clause of this Section 14) and such default continues for more than twenty (20) days after the earlier or (i) We have given notice of such
default to You, or (ii) You have actual knowledge of such default; or 

  

	•	 	 Other Agreements. The occurrence of any default (other than any default embodied in or covered by any other clause of this Section 14)
under any lease, loan, or other agreement or obligation of Yours involving any obligation which aggregates more than $250,000, or which default could reasonably be expected to have a Material Adverse Effect; or 

 

	•	 	 Judgments. The entry of (a) any judgment or arbitration award against You involving an award in excess of $250,000 or that could
reasonably be expected to have a Material Adverse Effect that is not covered by insurance by a solvent insurance carrier that has confirmed coverage in writing, has not been, discharged, bonded or stayed on appeal within ten (10) days; or
(b) any judgment or arbitration award against You in which You are enjoined, restrained or in any way prevented from conducting all or any material part of Your business or affairs. 

 

	•	 	 Change of Control. The occurrence of any event or transaction, including the sale or exchange of outstanding shares of Your capital stock or
the capital stock of any of Your Subsidiaries, or series of related events or transactions, resulting in (a) the holders of such outstanding capital stock immediately before consummation of such event or transaction, or series of related events
or transactions, do not, immediately after consummation of such event or transaction or series of related events or transactions, retain, directly or indirectly, capital stock representing at least 50% of the voting power of the surviving Person of
such event or transaction or series of related events or transactions, in each case without regard to whether You or any of Your Subsidiaries are the surviving Person, (b) any Person or “group” (other than a Person that is a
stockholder on the Closing Date) shall obtain “beneficial ownership” (as such terms are defined under Section 13d-3 of and Regulation 13D under the Securities Exchange Act of 1934), either directly or indirectly, of more than 25% of
Your outstanding capital stock having the right to vote for the election of directors under ordinary circumstances, or (c) You cease to own and control all of the economic and voting rights associated with all of the outstanding capital stock
of Your Subsidiaries. Notwithstanding the foregoing, a bona fide sale of Your equity securities in a public offering or to venture 

  
 11 

	 	 
capital investors shall not constitute an “Event of Default” hereunder so long as You identify to Us the venture capital investors prior to the closing of the transaction.

  

	•	 	 Investor Support. We have determined, in Our good faith judgment after consultation with You and Your investors, that it is the intention of
Your current equity investors to not continue to fund, or arrange for the funding of, You in the amounts and timeframe reasonably necessary to enable You to satisfy the Secured Obligations as they become due and payable. If You obtain equity
financing from third-party investors sufficient to satisfy the Secured Obligations as they become due and payable, no Event of Default will occur. 

  

	•	 	 Officers. The individuals holding the offices of Your Chief Executive Officer shall for any reason cease to hold such offices or be actively
engaged in Your day-to-day management, unless an interim successor approved by Your board of directors is appointed within ninety (90) days of such cessation. To be clear, such successor may act in this role on a temporary basis until such time
as a permanent successor is appointed. 

  
  

	17.	 WHAT HAPPENS UPON AN EVENT OF DEFAULT 

 
 If an Event of Default has occurred
and is continuing, We can at Our option, and without notice to You: 
  

	•	 	 Terminate Our commitment to make any future Advances under this Agreement; 

 

	•	 	 Terminate Our obligation to permit the principal, interest, fees, costs or other amounts owed by You to Us to remain outstanding;

  

	•	 	 Recover all sums due and accelerate and demand payment of all or any part of the principal, unpaid interest, fees, costs or other amounts owed by
You to Us and declare them to be immediately due and payable (provided, that upon the occurrence of a default of the type described in Section 16, Paragraph entitled “Bankruptcy, Attachment, Other”, the Promissory Notes
and all of the principal, interest, fees, costs or other amounts owed by You to Us shall automatically be accelerated and made immediately due and payable, in each case without any further notice or act). Upon after the occurrence and during the
continuation of an Event of Default, the unpaid principal and accrued interest on the Promissory Notes and advances and all outstanding principal, interest, fees, costs or other amounts owed by You to Us, including all professional fees and
expenses, shall thereafter bear interest at the Default Rate (as defined in Section 9); 

  

	•	 	 Enter Your premises, without notice and process of law and in compliance with Your security requirements, to remove and repossess the Collateral
without being liable to You for damages due to the repossession, except those resulting from Our or Our assignees’ negligence and charge You for the cost of repossession, storing and shipping the Collateral. With respect to any of premises that
You own, You hereby grant to Us a license to enter into possession of such premises and to occupy the same, without charge, in order to exercise any of Our rights or remedies provided herein, at law, in equity, or otherwise; and

  

	•	 	 Pursue any other remedy permitted by law, equity or otherwise. 

We may exercise all rights and remedies with respect to the Collateral under this Agreement or the other Loan Documents or otherwise
available to Us under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and
commingle the Collateral. You hereby grant to Us a license and right, to use, without charge, Your labels, patents, copyrights, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any property
of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral. All Our rights and remedies shall be cumulative and not exclusive. 

In addition to the power of attorney granted in Section 14, effective only upon the occurrence and during the continuance of an
Event of Default, You hereby irrevocably appoint Us (and any of Our designated officers, agents, attorneys or employees) as Your true and lawful attorney to (a) dispose of any Collateral; and (b) make, settle, and adjust all claims under
and decisions with respect to Your policies of insurance as they relate to the Collateral. Our appointment as Your attorney in fact, and each and every one of Our rights and powers, being coupled with an interest, is irrevocable until all of the
Secured Obligations (other than inchoate indemnity obligations) have been fully repaid and performed and Our obligation to provide Advances hereunder is terminated. 

  
 12 

  

	18.	 WHAT HAPPENS IF YOU ARE IN DEFAULT AND WE EXERCISE OUR REMEDIES 

 
 If an Event of Default has occurred
and is continuing, We may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable
preparation or processing, in such order as We may elect. Any such sale may be made either at public or private sale at Your place of business or elsewhere. You agree that any such public or private sale may occur upon Our ten (10) calendar
days’ prior written notice to You. We may require You to assemble the Collateral and make it available to Us at a place We designate that is reasonably convenient to Us. The proceeds of any sale, disposition or other realization upon all or any
part of the Collateral shall be applied in the following order of priorities: 
 First, to Us in an amount
sufficient to pay in full Our costs and professionals’ and advisors’ fees and expenses; 

Second, to Us in an amount equal to the then unpaid amount of all the principal, interest, fees, costs or other
amounts owed by You to Us under the Loan Documents, in such order and priority as We may choose in Our sole discretion; and 
 Finally, after the full, final, and indefeasible payment in Cash of all of the principal, interest, fees, costs or other amounts owed by You to Us, to any creditor holding a junior Lien on the
Collateral, or to You or Your representatives or as a court of competent jurisdiction may direct. 
 We shall be deemed to have
acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC. 
  

 

	19.	 DOCUMENTS YOU WILL PROVIDE US 

 
 Upon signing this Agreement You will provide
Us with: 
  

	•	 	 Executed originals of this Agreement, and all other documents and instruments that We may reasonably require; 

 

	•	 	 Officer’s Certificate of incumbency and authority; 

 

	•	 	 Certified copy of resolutions of Your board of directors approving this Agreement and the associated Warrant Agreement;

  

	•	 	 Certified copy of Certificate of Incorporation and By-Laws as amended through the date that the Parties enter into this Agreement;

  

	•	 	 A certificate of good standing from Your state of incorporation and similar certificates from all other jurisdictions where You do business and
where the failure to be qualified would have a Material Adverse Effect; 

  

	•	 	 Payment of the Facility Fee for the Commitment Amount as denoted on Page 1 of this Agreement; 

 

	•	 	 A completed Exhibit C; and 

  

	•	 	 Any such other documents as We may reasonably request. 

 So long as there are any unpaid principal, interest, fees, costs or other amounts owed by You to Us, or We have any obligation to make any additional Advances, You shall provide Us with:

 Landlord/Mortgagee Waiver. You agree to provide Us with a Landlord/Mortgagee Waiver with respect to the
Equipment so that Your landlord or mortgagee does not restrict Our access to the Equipment or claim any interest in the Equipment. Such waiver shall be in a form satisfactory to Us. 

Financial Statements. Within thirty (30) days after the end of each month, You will provide to Us a monthly unaudited income
statement; unaudited balance sheet and unaudited statement of cash flows prepared in accordance with generally accepted accounting principles. Within two hundred ten (210) days of every fiscal year end, You will provide Us audited

  
 13 

 
financial statements accompanied by an audit report and opinion of the independent certified public accountants. You will provide Us any additional information (including, but not limited to, tax
returns, income statements, balance sheets and names of principal creditors) as We reasonably believe are necessary to evaluate Your continuing ability to meet financial obligations. These statements should be emailed to Us at
financials@triplepointcapital.com. or upon Our prior approval, facsimiled or mailed to Us at the address listed on Page 1 of this Agreement. 
 Certificate of Compliance. On an annual basis We will provide You with a Certificate of Compliance, attached as Exhibit D and a list of all Equipment subject to this Agreement and the Loan
Documents. Upon receipt You will have thirty (30) days to provide Us with the completed Certificate of Compliance. 
  

 

	20A.	 RIGHT TO INVEST 

 
 You grant Us the right to invest up
to Two Hundred Fifty Thousand and No/100 Dollars ($250,000), in Your Next Round at Our sole discretion. You agree to provide Us with at least twenty (20) days prior written notice of the proposed date of the Next Round, which notice shall
include the final terms, conditions and pricing of the Next Round. 
  

 

	20B.	 RIGHT OF FIRST REFUSAL 

 
 You agree that so long as this
Agreement remains in effect, You shall provide Us with an exclusive, first right to review all future equipment and working capital financings needs of You. Upon receipt of any request for proposal from You, We shall have no less than ten
(10) days (the “Exclusivity Period”) to review such request and, if We so elect, to respond to You by declining such request or making a proposal. You shall not discuss with, or offer such potential financing opportunity to,
any other person or entity except Us until the earlier of (i) the lapse of the Exclusivity Period or (ii) We declines to bid on such opportunity. Nothing contained in this section shall obligate Us to respond to or otherwise bid on any
such request for proposal offered by You under this Agreement nor shall this clause be construed as a commitment on the part of Us to extend credit to You. Nothing contained in this section shall obligate You to accept any proposal offered by Us.
The right of first refusal offered by You under this Agreement is a material inducement to Us entering into this Agreement with You. 
  

 

	21.	 OTHER LEGAL PROVISIONS YOU WILL ABIDE BY 

 
 Continuation of Security
Interest. This is a continuing agreement and the grant of the security interest and Lien hereunder shall remain in full force and effect and all of Our rights, powers and remedies shall continue to exist until all of the principal, interest,
fees, costs or other amounts owed by You to Us under this Agreement (other than inchoate indemnity obligations) are fully and finally paid in cash and We have no further obligation to make Advances. We shall file a termination statement and provide
proof of filing to You within three (3) days after the full and final payment in cash of all of the principal, interest, owed by You to Us hereunder, reassigning to You, without recourse except for Our acts, the Collateral and all rights
conveyed hereby and returning possession of the Collateral to You. Our rights, powers and remedies shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the
rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to Our other rights, powers and remedies. 
 Entire Agreement. This Agreement and associated Promissory Notes supersede all other oral or written agreements or understandings between the Parties concerning the Collateral. ANY AMENDMENT OF
THIS AGREEMENT OR A PROMISSORY NOTE MAY ONLY BE ACCOMPLISHED THROUGH A DOCUMENT WITH SIGNATURES FROM EACH OF THE PARTIES. 

Headings. Headings used in this Agreement are for reference and convenience of the Parties only and shall have no substantive
effect in the interpretation of this Agreement. 
 No Waiver. No action taken by Us or You will be deemed to constitute a
waiver of compliance with any representation, warranty or covenant contained in this Agreement or Promissory Note. The waiver by Us of a breach of any provision of this Agreement or a Promissory Note will not operate or be construed as a waiver of
any subsequent breach. 

  
 14 

 Survival of Obligations. The indemnification, obligations, representations and
warranties contained in this Agreement, any Promissory Note or in any document delivered in connection with those agreements are for the benefit of The Parties and survive the execution and delivery of this Agreement. Further, such indemnification
shall survive expiration and termination of this Agreement. 
 Successors and Assigns. The provisions of this Agreement
and the other Loan Documents shall inure to the benefit of and be binding on You and Your permitted assigns (if any). You shall not assign Your obligations under this Agreement, the Promissory Notes or any of the other Loan Documents without Our
express prior written consent, and any such attempted assignment shall be void and of no effect. You acknowledge and understand that We may sell and assign all or part of Our interest hereunder and under the Promissory Note(s) and all other related
Loan Documents to any person or entity to be known as assignee provided, however, that if no Event of Default has occurred, We may not sell and assign any part of Our interest to a direct competitor of You, as determined by Your board of directors
in good faith. In addition, We may not sell and assign Our obligation to make Advances under this Agreement without Your prior written consent, such consent not to be unreasonably withheld. After such assignment the term “We”
“Us” and “Our” as used in the Loan Documents will mean and include such assignee, and such assignee will be vested with all Our rights, powers and remedies hereunder and shall have Our duties with respect to the interest that You
have granted Us; but with respect to any such interest not so transferred, We shall retain all rights, powers and remedies. No such assignment will relieve You of any of Your obligations. We agree that in the event of any transfer of the Promissory
Note(s), We will denote on the Promissory Note a notation as to the portion of the principal and interest of the Promissory Note(s), which shall have been paid at the time of such transfer and the date of the transfer. 

Consent To Jurisdiction And Venue. All judicial proceedings arising in or under or related to this Agreement, the Promissory Notes
or any of the other Loan Documents may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally:
(a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of
jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Promissory Notes or the other Loan Documents. Service of process on any party hereto
in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing herein shall
affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 Mutual Waiver Of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert
person and the Parties wish applicable state and federal laws to apply (rather than arbitration rules), the Parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT
THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU.
IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE
CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED
BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP REMEDIES, FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES.
THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES
ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. THIS WAIVER EXTENDS TO ALL SUCH CLAIMS, INCLUDING CLAIMS THAT INVOLVE PERSONS OTHER THAN YOU AND US; CLAIMS THAT ARISE OUT OF OR ARE IN ANY WAY CONNECTED TO THE RELATIONSHIP BETWEEN YOU
AND US; AND ANY CLAIMS FOR DAMAGES, BREACH OF CONTRACT, SPECIFIC PERFORMANCE, OR ANY EQUITABLE OR LEGAL RELIEF OF ANY KIND, ARISING OUT OF THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR ANY OF THE EXCLUDED AGREEMENTS. 

  
 15 

 Professional Fees. You promise to pay or reimburse on demand, any and all
reasonable professional fees and expenses incurred by Us whether before or after the execution of this Agreement in connection with or related to: the Loan Documents, the Excluded Agreements, or the Secured Obligations; the administration,
collection, or enforcement of the Secured Obligations; amendment or modification of the Loan Documents and the Excluded Agreements; any waiver, consent, release, or termination under the Loan Documents or Excluded Agreements; the protection,
preservation, sale, lease, liquidation, inspection, audit, disposition of or other action related to the Collateral or the exercise of remedies with respect to the Collateral; or any legal, litigation, administrative, arbitration, or out of court
proceeding in connection with or related to You or the Collateral, and any appeal or review thereof; and any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to You,
the Collateral, the Loan Documents, or the Excluded Agreements, including representing Us in any adversary proceeding or contested matter commenced or continued by or on behalf of Your estate, and any appeal or review thereof. Our professional fees
and expenses shall include the reasonable fees or expenses for Our attorneys, accountants, auditors, auctioneers, liquidators, appraisers, investment advisors, environmental and management consultants, or experts engaged by Us in connection with the
foregoing. Your promise to pay all of Our reasonable professional fees and expenses is part of the Secured Obligations under this Agreement. Notwithstanding anything to the contrary contained herein, You shall not be liable for any professional fees
or expenses incurred by Us to the extent (i) arising from any Indemnified Person’s gross negligence or willful misconduct, or (ii) arising in connection of Our assignment, sale or participation of all or any portion of Our rights and
obligations under this Agreement, the Loan Documents or any Excluded Agreement. With regard to professional fees and expenses incurred by Us prior to the Closing Date, You shall not be obligated to reimburse any amounts in excess of $7,500.

 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against You for liquidation or reorganization, if You become insolvent or make an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part
of Your assets, or if any payment or transfer of Collateral is recovered from Us. The Loan Documents, the Secured Obligations and Our Lien on the Collateral shall continue to be effective, or shall be revived or reinstated, as the case may be, if at
any time payment and performance of the Secured Obligations or any transfer of Collateral to Us, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Us or by
any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any
payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and
reinstated except to the extent of the full, final, and indefeasible payment to Us in cash. 
 Notices. Any
notice, request or other communication to either of the Parties by the other will be given in writing and deemed received upon the earlier of (1) actual receipt or (2) 3 days after mailing if mailed postage prepaid by regular or airmail to
Us or You, at the address set out on Page 1 of this Agreement, (3) 1 day after it is sent by courier or overnight delivery 

Applicable Law. This Agreement and any Promissory Note will have been made, executed and delivered in the State of
California and will be governed and construed for all purposes in accordance with the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all such
counterparts together constitute one and the same instrument. 
 Signatures. This Agreement and any Promissory Note may
be executed and delivered by facsimile or transmitted electronically in either Tagged Image Format Files (“TIFF”) or Portable Document Format (“PDF”) and, upon such delivery, the facsimile, TIFF or PDF signature, as applicable,
will be deemed to have the same effect as if the original signature had been delivered to the other party. 

Confidentiality. All financial information (other than any such information contained in periodic reports filed by You with the
Securities and Exchange Commission) disclosed by You to Us that is marked “Confidential” or should reasonably be known to Us to be confidential shall be considered confidential for purposes of this Agreement. In handling any confidential
information, We will exercise the same degree of care that We exercise for Our own proprietary information, but disclosure of information may be made (i) to Our subsidiaries or Affiliates in connection with their business with You, (ii) to
prospective transferees or purchasers of any interest in the Loans (provided, however, We shall use best efforts in 

  
 16 

 
obtaining such prospective transferee’s agreement of the terms of this provision and any purchaser shall be agreeing to assume the obligations hereunder and therefore agreeing to abide by
the provisions hereof, including, without limitation, the provisions of this Section), (iii) as We deem necessary or appropriate to any bank, financial institution or other similar entity, provided, however, that such bank, financial
institution or other similar entity agrees in writing to maintain the confidentiality of such information, (iv) to S&P, Moody’s, Fitch and/or other ratings agency, as We deem necessary or appropriate, provided, however, that such
financial institution or ratings agency shall be informed of the confidentiality of such, (v) as required by law, regulation, subpoena, or other order, (vi) as required in connection with Our examination or audit and (vii) as We
consider appropriate exercising remedies under this Agreement after the occurrence and during the continuance of an Event of Default. Confidential information does not include information that either: (a) is in the public domain or in Our
possession when disclosed to Us, or becomes part of the public domain after disclosure to Us through no fault of Ours; or (b) is disclosed to Us by a third party, if We do not know that the third party is prohibited from disclosing the
information. Notwithstanding the above, You hereby consent to the use by Us of Your company name and logo on Our website for marketing purposes only. Such use may reference the type of credit facility but will not indicate the amount of the credit
facility without Your prior written approval. 
  
  

	22.	 DEFINITIONS 

 
 Capitalized terms used in this
Agreement shall have the following meanings: 
 “Advance Date” means the day on which We make and Advance to
You. 
 “Business Day” means any day other than a Saturday, Sunday or other day on which banking institutions
in the State of California are authorized or required by law or other government action to close. 
 “Closing Date” means
June 20, 2011. 
 “Collateral” has the meaning given to it in Section 10. 

“Commitment Increase Request Notice” has the meaning given to it in Section 3. 

“Default” means any event that, with the passage of time or notice or both would, unless cured or waived, become an
Event of Default. 
 “Default Rate” has the meaning given to it in Section 9. 

“Designated Information” has the meaning given to it in Section 6. 

“Equipment” has the meaning given to it in Section 1. 

“Event of Default” has the meaning given to it in Section 16. 

“Excluded Agreements” means (i) the Warrant Agreement; and (ii) any stock purchase agreement, options, or
other warrants to acquire, or agreements governing the rights of, any capital stock or other equity security, or any common stock, preferred stock, or equity security issued to or purchased by Us or its nominee or assignee. 

“GAAP” means United States generally accepted accounting principles, consistently applied, as in effect from time to
time. 
 “Indebtedness” means, of any Person, at any date, without duplication and without regard to whether
matured or unmatured, absolute or contingent: (i) all obligations of such Person for borrowed money; (ii) all obligations of such Person evidenced by bonds, debentures, notes, or other similar instruments; (iii) all obligations of
such Person to pay the deferred purchase price of property or services; (iv) all obligations of such Person as lessee under capital leases; (v) all obligations of such Person to reimburse or prepay any bank or other Person in respect of
amounts paid under a letter of credit, banker’s acceptance, or similar instrument, whether drawn or undrawn; (vi) all obligations of such Person to purchase securities which arise out of or in connection with the sale of the same or
substantially similar securities; (vii) all obligations of such Person to purchase, redeem, exchange, convert or otherwise acquire for value any capital stock of such Person or any warrants, rights or options to acquire such capital stock, now
or hereafter outstanding, except to the extent that such obligations remain performable solely at 

  
 17 

 
the option of such Person; (viii) all obligations to repurchase assets previously sold (including any obligation to repurchase any accounts or chattel paper under any factoring, receivables
purchase, or similar arrangement); (ix) obligations of such Person under interest rate swap, cap, collar or similar hedging arrangements; and (x) all obligations of others of any type described in clause (i) through clause
(ix) above guaranteed by such Person. 
 “Investment” means any beneficial ownership (including stock,
partnership or limited liability company interest or other securities) of any Person, or any loan, advance or capita! contribution to any Person. 
 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or
arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and the filing of any financing statement (other than a precautionary financing
statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction. 
 “Loan Documents” means this Agreement, the Promissory Notes, all UCC Financing Statements, and any other documents executed in connection with the Secured Obligations or the transactions
contemplated hereby, including those documents described on the Schedule of Documents, as the same may from time to time be amended, modified, supplemented or restated; provided that the Loan Documents shall not include any of the Excluded
Agreements. 
 “Material Adverse Effect” means a material adverse effect on (i) Your business, operations,
properties, assets or condition (financial or otherwise), (ii) Your ability to perform the Secured Obligations in accordance with the terms of the Loan Documents or Our ability to enforce any of Our rights and remedies with respect to the
Secured Obligations in accordance with the terms of the Loan Documents, or (iii) Our Liens on the Collateral or the priority of such Liens. 
 “Merger Event” means (i) any reorganization, consolidation or merger (or similar transaction or series of transactions) by You or any of Your subsidiaries with or into any other
Person; (ii) any transaction, including the sale or exchange of outstanding shares of Your capital stock, in which the holders of Your outstanding capital stock immediately before consummation of such transaction or series of related
transactions do not, immediately after consummation of such transaction or series of related transactions, retain capital stock representing at least 50.0% of the voting power of the surviving corporation of such transaction or series of related
transactions (or the parent corporation of such surviving corporation if such surviving corporation is wholly owned by such parent corporation), in each case without regard to whether You are the surviving corporation; provided that a bona fide sale
of Your equity securities in a public offering or to venture capital investors shall not constitute an “Merger Event” hereunder so long as You identify to Us the venture capital investors prior to the closing of the transaction, or
(iii) the sate, license or other disposition of all or substantially all of Your assets. 
 “Next Round”
means the first equity financing, or extension of an existing round of equity financing, occurring after the Closing Date, in which You issue preferred stock for aggregate gross cash proceeds of at least Two Million Dollars ($2,000,000) (with
aggregate proceeds to include the amounts that the investors in such financing have committed to invest, in accordance with the terms of the financing documents after the initial closing under such documents and to exclude any amounts receivable
upon, or attributable to, conversion or cancellation of indebtedness), whether in a single or multiple closings and whether in related or unrelated financings. 
 “Permitted Liens” means any and all of the following with regard to the Collateral: (i) Liens in Our favor; (ii) Liens for taxes, fees, assessments or other governmental charges
or levies, either not delinquent or being contested in good faith by appropriate proceedings, provided that such Liens do not have priority over any of Our Liens and You maintain adequate reserves in accordance with GAAP; (iii) Liens
securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Your business and imposed without action of such parties, provided that the payment
thereof is not yet required, remains payable without penalty or is being contest in good faith; and; (iv) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder. 

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization,
association, corporation, limited liability company, institution, public benefit corporation, other entity or government (whether federal, state, county, city, municipal, local, foreign, or otherwise, including any instrumentality, division, agency,
body or department thereof). 

  
 18 

 “Promissory Note” has the meaning given to it in Section 2. 

“PT” means Pacific Time. 
 “Secured Obligations” means Your obligation to repay to Us all Advances (whether or not evidenced by any Promissory Note), together with all principal, interest, fees, costs, professional
fees and expenses, or other liabilities or obligations for monetary amounts owed by You to Us, including the indemnity and insurance obligations in Sections 12,15 and 21 hereof and including such amounts as may accrue or be incurred before or after
default or workout or the commencement of any liquidation, dissolution, bankruptcy, receivership or reorganization by or against You, whether due or to become due, matured or un-matured, liquidated or un-liquidated, contingent or non-contingent, and
all covenants and duties of any kind or nature, present or future, arising under this Agreement, the Promissory Notes, or any of the other Loan Documents, as the same may from time to time be amended, modified, supplemented or restated, whether or
not such obligations are partially or fully secured by the value of Collateral; provided, that the Secured Obligations shall not include any of Your Indebtedness or obligations arising under or in connection with the Excluded Agreements.

 “Soft Costs” has the meaning given to it in Section 1. 

“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California;
provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Secured Party’s Lien on any Collateral is governed by the Uniform Commercial Code
as the same is, from time to time, in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the
provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein or in the other Loan Documents terms that are defined in the UCC and used
herein or in the other Loan Documents shall have the meanings given to them in the UCC. 
 “Warrant Agreement”
means either the Warrant Agreement dated the date hereof between the Parties issued in connection with this Agreement or any other Warrant Agreement between the Parties issued in connection with this Agreement. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,”
“subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. The terms “herein,” “hereof and
“hereunder” and other words of similar import refer to this Agreement as a whole, including all Exhibits, Annexes and Schedules, and not to any particular Section, subsection or other subdivision. 

Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the
plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, feminine and neuter genders. The words “including,” “includes” and “include” shall be deemed to be followed by the
words “without limitation,” the word “or” is not exclusive; references to Persons include their respective successors and assigns (to the extent and only to the extent permitted by this Agreement and the Loan Documents) or, in
the case of governmental Persons, Persons succeeding to the relevant functions of such Persons; and all references to statutes and related regulations shall include any amendments of the same and any successor statutes and regulations. Unless
otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in
accordance with GAAP, consistently applied. 
 (Signature Page to Follow) 

  
 19 

 IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement as of the
day and year first above written. 
  

							
	 BORROWER:
	 		 	You:	  	GENOMATICA, INC.
				
		 		 	 Signature:
	  	 /s/ Christophe Schilling

				
		 		 	 Print Name:
	  	 Christophe Schilling

				
		 		 	 Title:
	  	 Chief Executive Officer

				
	Accepted in Menlo Park, California:	 		 		  	
				
	 LENDER:
	 		 	Us:	  	TRIPLEPOINT CAPITAL LLC
				
		 		 	 Signature:
	  	 /s/ Sajal Srivastava

				
		 		 	 Print Name:
	  	 Sajal Srivastava

				
		 		 	 Title:
	  	 Chief Operating Officer

 [Signature Page to Plain English Equipment Loan and Security Agreement] 

  
 20 

 EXHIBIT A 
 PLAIN ENGLISH PROMISSORY NOTE 
 This is a Plain English Promissory Note
dated “[MONTH, DAY, YEAR]” by and between TRIPLEPOINT CAPITAL LLC AND GENOMATICA, INC.. The words “We”, “Us”, “Our”, refer to the Lender, which is TRIPLEPOINT CAPITAL LLC. The words “You” or
“Your” refers to the Borrower, which is GENOMATICA, INC. and not any individual. The words “the Parties” refers to both, TRIPLEPOINT CAPITAL LLC AND GENOMATICA, INC. 

PROMISSORY NOTE INFORMATION 
  

					
	Facility Name 	  	Facility Number	  	Promissory Note Number
			
	Equipment Loan Facility	  	        -LO-0	  	        -LO-01H/S
			
	Principal Amount	  	Collateral	  	Loan Term
			
	$            	  	 Equipment
  

See Exhibit A
	  	     months
			
	Interest Rate	  	Payment Amount	  	End of Term Payment
			
	        %	  	$            	  	$            
			
	Funding Date	  	First Payment Date	  	Maturity Date
			
	            , 200  	  	            , 200  	  	            ,00  

 CONTACT INFORMATION 

 

					
	Name	  	Address For Notices 	  	Contact Person 
			
	TriplePoint Capital LLC	  	 2755 Sand Hill Rd., Ste. 150
 Menlo Park, CA 94025
 Tel: (650) 854-2090

Fax: (650) 854-2094
	  	Sajal Srivastava, COO
			
	Customer Name	  	Central Billing Address	  	Contact Person
			
	Genomatica, Inc.	  	 10520 Wateridge Circle
 San Diego, CA 92121
 858-362-8571
	  	 Tom McDonald, Sr. Dir. Finance
 Tel: 858-362-8563
 Fax: 858-824-1772

email: tmcdonald@genomatica.com

 FOR VALUE RECEIVED, You hereby promise to pay to the order of TRIPLEPOINT CAPITAL LLC or
the holder of this Plain English Promissory Note at 2755 Sand Hill Road, Ste. 150, Menlo Park, CA, 94025 or such other place of payment as the holder of this Plain English Promissory Note may specify from time to time in writing, in lawful money of
the United States of America, the principal amount of                         /100 Dollars
($            ) together with interest at      percent (    %) per annum from the date of this Plain English Promissory Note to maturity of each
installment on the principal remaining unpaid, such principal and interest to be paid as stated on Page 1 of this Plain English Promissory Note and the attached amortization schedule. In addition to Your final payment, You will pay Us an amount
equal to          percent (    %) of the principal amount of this Plain English Promissory Note on the Maturity Date. Interest shall be computed daily on the basis of a year consisting
of 360 days for the actual number of days occurring 

  
 21 

 
in the period for which such interest is payable. Any payments made under this Plain English Promissory Note shall not be available for re-borrowing. 

This Plain English Promissory Note is the Promissory Note referred to in, and is executed and delivered in connection with, that certain
Plain English Equipment Loan and Security Agreement dated as of                     , 2011 by and between the Parties (as the same may from time to
time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of that Loan Agreement and the other documents executed in connection with all principal, interest,
fees or other liabilities owed by You to Us. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. 
 You waive presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. 

This Plain English Promissory Note has been negotiated and delivered to Us and is payable in the State of California. This Plain English
Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction.

  

			
	YOU:	 	GENOMATICA, INC.
		
	Signature:	 	  

		
	Print Name:	 	 Christophe Schilling

		
	Title:	 	 Chief Executive Officer

 [ATTACH AMORTIZATION SCHEDULE] 

[ATTACH EXHIBIT A - EQUIPMENT] 

  
 22 

 EXHIBIT B 
 ADVANCE REQUEST 
  

							
	To:	  	 TRIPLEPOINT CAPITAL LLC
 2755
Sand Hill Road Ste. 150
 Menlo Park, CA 94025
 Attention: Customer Administrations
 Fax (650) 854-1850
	  	Date:                            
	  	

 GENOMATICA, INC., (“We” or “Us”), hereby request from TRIPLEPOINT CAPITAL LLC
(“You”) an Advance in the amount of $             on             ,          (at
least five (5) business days from today) pursuant to the Plain English Equipment Loan and Security Agreement between the Parties (the “Loan Agreement”). Capitalized terms not otherwise defined herein shall have the meanings contained
the Loan Agreement. 
 We instruct You to please: 

 

	 	(a)	 Issue a check payable to Us              

or 
  

	 	(b)	 Transfer Funds to our account          

Bank: 
 Address: 
 ABA Number: 

Account Number: 
 Account Name: 
 We represent that: 

 

	 	•	 	 No event or circumstance has occurred or exists which individually or together with any other event or circumstance, has had or could reasonably be
expected to have a Material Adverse Effect; 

  

	 	•	 	 The representations, covenants and warranties set forth in the Loan Agreement and in the Plain English Warrant Agreement are and shall be true,
complete and correct in all material respects on and as of the date the requested Advance is funded with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier
date (in which case, those representations and warranties remain true, complete and correct in all material respects as of such date); provided, however, that such materiality qualifiers shall not be applicable to any representations and warranties
that already are qualified or modified by materiality in the text thereof; 

  

	 	•	 	 We are in compliance with all the terms and provisions set forth in any document related to this Advance (including, without limitation,
Section 7 of the Loan Agreement); and 

  

	 	•	 	 As of the date hereof and the date of the funding of the requested Advance, no fact or condition exists that would (or would, with the passage of
time, the giving of notice, or both, would) constitute an Event of Default under the Loan Agreement; and 

  
 23 

	 	•	 	 We understand and acknowledge that You have the right to review the financial information supporting this representation and based upon such review
in Your reasonable discretion You may decline to fund the requested Advance. 

 We hereby represent that Our
organizational status and locations are as set forth below: 
  

			
	Name:	  	Genomatica, Inc.
		
	Type of Organization:	  	C-Corporation
		
	State of Organization:	  	Delaware
		
	Organization File Number:	  	4441521

 We hereby represent and warrant to You that the street addresses, cities, states and postal codes of Our
current locations are as follows: 
  

			
	Chief Executive Office:	  	
		
	Principal Place of Business:	  	
		
	Locations of Collateral:	  	

 Executed this      day of
            ,          by: 
  

			
	WE:	 	GENOMATICA, INC.
		
	Signature:	 	  

		
	Print Name:	 	 Christophe Schilling

		
	Title:	 	 Chief Executive Officer

  
 24 

 EXHIBIT C 
 YOUR NAME, LOCATIONS, AND OTHER INFORMATION 
 1. You hereby represent and warrant
and to Us that Your current name and organizational status on the Closing Date is as follows: 
  

			
	Name:	  	Genomatica, Inc.
		
	Type of Organization:	  	C-Corporation
		
	State of Organization:	  	Delaware
		
	Organization File Number:	  	4441521

 2. You hereby represent and warrant to Us that for five (5) years prior to the date of this
Agreement, You did not do business under any other name or organization or form except the following: 
  

			
	Name:	  	None
		
	Used during dates of:	  	
		
	Type of Organization:	  	
		
	State of Organization:	  	
		
	Organization File Number:	  	

 3. Your fiscal year ends on December 31st 

4. Your federal employer tax identification number is 33-0831527 

5. You hereby represent and warrant to Us that the street addresses, cities, states and postal codes of Your current locations and
locations where any Collateral may be located as of the Closing Date are: 
  

			
	Chief Executive Office:	  	 10520 Wateridge Circle
 San
Diego, CA 92121

		
	Principal Place of Business:	  	 10520 Wateridge Circle
 San
Diego, CA 92121

		
	Other Locations:	  	 Tate & Lyle
 2200 East
Eldorado Street
 Decatur, IL 62525

  
 25 

 EXHIBIT D 
 CERTIFICATE OF COMPLIANCE 

This Certificate of Compliance shall reference that certain Plain English Loan and Security Agreement dated as of
                    , 2011, by and between TRIPLEPOINT CAPITAL LLC and GENOMATICA, INC. (the “Loan Agreement”). All terms not defined in
this Certificate of Compliance shall have the same meanings as in the Loan Agreement. Pursuant to the terms of the Loan Agreement, GENOMATICA, INC. hereby certifies, the following as of “[MONTH, DAY, YEAR]” : 

 

	 	•	 	 We are in compliance as of the date of this Certificate of Compliance with all required covenants unless otherwise noted and attached to this
Certificate of Compliance. 

  

	 	•	 	 As of the date of this Certificate of Compliance all representations and warranties in the Loan Agreement are true and correct in all material
respects except to the extent such representations and warranties expressly relate to an earlier date (in which case, those representations and warranties remain true as of such date). 

 

	 	•	 	 The locations of all Equipment on the attached list and subject to the Loan Agreement are true and correct. 

 

			
		 	GENOMATICA, INC.
		
	Signature:	 	  

		
	Print Name:	 	 Christophe Schilling

		
	Title:	 	 Chief Executive Officer

 [ATTACH LIST OF EQUIPMENT] 

  
 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]